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ABSTRACT
Objectives The study aimed to estimate the prevalence 
of, and associations, with HIV and metrics of HIV care 
engagement in a representative population of gay, 
bisexual and other men who have sex with men (GBMSM) 
and transgender persons (TP) who have sex with men 
(GBMSM/TP)
Setting Urban districts of Nairobi, Kenya.
Design Cross- sectional.
Participants 608 eligible participants were identified 
through respondent- driven sampling over 19 waves of 
recruitment arising from ten seeds between May and 
December 2017. Inclusion criteria were: age >18 years; 
Nairobi residence; male sex assignment at birth or current 
identification as male, and recent consensual sex with 
male partners. Exclusion criteria were: missing or invalid 
recruitment coupon; repeat registration; intoxication at 
study visit.
Primary and secondary outcome measures HIV 
status measured using Determine Alere HIV 1/2 and First 
Response HIV 1–2.0 and GeneXpert HIV- 1 Qual. Self- 
reported metrics of HIV status awareness, antiretroviral 
use and objective quantification of viral suppression using 
GeneXpert HIV- 1 VL.
Results 26.4% (286/618) were HIV positive of whom 
76.6% were status aware, 65.3% were on antiretroviral 
therapy (ART), and 47.4% were virally suppressed (<50 
copies/mL). Participants 18–22 years were less likely to 
be status aware, be receiving ART or to have achieved 
viral suppression. Mean log viral load was 3.14 log 
higher in 18–22 years compared with older participants. 
Bacterial sexually transmitted infections were common 
at both urethral and rectal sites and most infections 
were asymptomatic by self- report (rectal 82.2%, urethral 
82.3%).
Conclusions Engagement in the HIV diagnosis and care 
cascade among GBMSM/TP in Nairobi is markedly better 
than in most sub- Saharan African countries, yet falls short 
of achievements for the general population in Kenya and 
for GBMSM in high income settings. Young GBMSM/TP are 
least well served by the current configuration of adult key 
population services, and programmes should identify and 
address the sexual, social and developmental needs of 
adolescent and young key populations.
BACKGROUND
Gay, bisexual and other men who have sex 
with men (GBMSM) and transgender persons 
(TP) bear disproportionate burdens of HIV 
risk and HIV infection around the world,1–3 
including in generalised epidemic settings in 
sub- Saharan Africa.4 5 Structural and cultural 
obstacles, including criminalisation, institu-
tional homophobia and societal antipathy 
towards these groups continue to challenge 
efforts to provide equitable access to effec-
tive HIV prevention and treatment, partic-
ularly in sub- Saharan Africa.6 International 
agencies highlight the harmful consequences 
of unequal access to prevention and treat-
ment on members of these populations and 
to efforts to curb national HIV epidemics.7 
Yet despite clear targets for increasing status 
awareness and antiretroviral therapy (ART) 
uptake among key populations,8 very few 
sub- Saharan African countries conduct 
Strengths and limitations of this study
 ► Population representative estimates of HIV preva-
lence and HIV care cascade for this key population 
in Nairobi, employing methods to avoid sampling bi-
ases common for marginalised group research.
 ► Comprehensive array of HIV and sexually transmit-
ted infection diagnostics able to highlight the prev-
alence of both infections undetectable by standard 
Kenyan national guidelines.
 ► Inclusion criteria limited to adults eighteen and over, 
precluding insights into HIV risk and care engage-
ment in younger adolescents.
 ► HIV status awareness and care engagement mea-
sures may not be accurately reporting in self- 
completed surveys, despite known benefits of 
computer- assisted methods to reduce social dis-
ability bias.
 ► Cross- sectional surveys cannot infer direction of 
causation where this is not implicit.
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surveillance to monitor the effectiveness and coverage of 
treatment programmes for these populations.9 10
Kenya has a declining generalised epidemic with an 
adult prevalence estimated at 4.9% in 2018, compre-
hensive national prevention and treatment responses 
including oral pre- exposure prophylaxis (PrEP), post- 
exposure prophylaxis, voluntary male circumcision, test 
and treat, and broad availability of viral load testing to 
support HIV care.11 The Kenya Population- based HIV 
Impact Assessment study demonstrated the progress 
toward achievement of UNAIDS 90- 90- 90 targets in a 
national survey of the general population12: in 2018, 
79.5% of adult persons living with HIV/AIDS (PLWH) 
(15–49 years) were aware of their HIV status, of whom 
90.6% were receiving ART, of whom 90.9% (or 72% of 
all PLWH) were virally suppressed.12 HIV surveillance is 
less comprehensive for GBMSM and TP in Kenya, despite 
a decade of research indicating high levels of need and 
poor service access. HIV prevalence was 18% among 
GBMSM/TP in Nairobi in 2010—more than three times 
that among the general population—and only 34% of 
those living with HIV were aware of their status.13 In 
Eastern Kenya, outcomes of HIV care for GBMSM after 
treatment initiation, as assessed by virological suppres-
sion at 12 months, was just 63%, positively influenced 
by high coping self- efficacy and negatively influenced by 
intercourse practices thought to attract stigma.14
Kenya’s HIV response is inclusive of key populations, 
including GBMSM and TP and national AIDS control 
policies include aims to enhance HIV prevention and 
treatment service for these populations in line with the 
WHO recommended package of key population interven-
tions.15 16 This has enabled a mixed model of prevention 
and care delivery through non- governmental organisa-
tions, private providers and state clinics largely concen-
trated in major cities. While diversification of sexual 
health provision may well have improved cultural compe-
tence and accessibility of services for these populations, 
there are no population representative estimates of the 
entire HIV diagnosis and care cascade for GBMSM/TP 
populations to monitor the effectiveness of this service 
model.
We aimed to (1) update the prevalence of HIV and 
other sexually- transmitted infections (STIs) in a popu-
lation representative sample of cisgender male and TP 
who have sex with men living in Nairobi, (2) describe 
the HIV care cascade and viral load among GBMSM and 
TP living with HIV and (3) assess associations with prev-




Respondent- driven sampling (RDS) was used to recruit 
618 participants between May and December 2017 
following established methods.17 Seed participants were 
identified to the study by three community organisations 
who provide services to GBMSM communities in Nairobi 
(Gay and Lesbian Coalition of Kenya (GALCK), Ishtar 
MSM and Health Options for Young Men on STI/
HIV/AIDS (HOYMAS). Following formative qualitative 
research, ten seeds were chosen to optimise diversity in 
age, marital status, gender identity, socioeconomic status 
and district of residence within Nairobi County.
Each participant was issued two recruitment coupons 
and instructions on how to recruit further eligible partic-
ipants from their social networks. Inclusion criteria were: 
possession of a valid study coupon; age 18 or over; male 
gender assignment at birth or current identification as a 
man; residence within 50 km of Nairobi, and consensual 
anal or oral sexual activity with a man in the previous 
twelve months. Coupons detailed the location and contact 
details for the study site but disclosed no information 
about the purpose of the study. Coupons were uniquely 
numbered to verify recruiter- recruit links and coupon 
legitimacy. The opportunity for coupon duplication 
was reduced by use of non- standard grade watermarked 
paper, date stamping and limited period of validity after 
issue. Participants were reimbursed Ksh300 (~US$3) for 
each recruit they referred to the study who subsequently 
participated.
Study procedures
Seeds and coupon recipients who satisfied eligibility 
criteria underwent informed consent procedures with 
study staff. Recipients were ineligible if they reported 
coupon receipt from a stranger, coercion to attend or 
previous participation in the study. Unique identity was 
established using a commercially available digital finger-
print scanner.
Participant characteristics and behaviour were collected 
via self- completed SurveyGizmo questionnaire imple-
mented in English and Kiswahili on touch- screen tablets 
taking approximately 90 min to complete (online supple-
mental material). The questionnaire covered multiple 
domains including demographic characteristics; sexual 
behaviour; alcohol and other substance use; knowledge 
of HIV transmission risks; use of existing HIV/STI preven-
tion methods; recent anogenital symptoms suggestive of 
STI; experiences of sexuality- related stigma, discrimina-
tion or violence.18 19 Sex was defined as any occurrence of 
anal or vaginal intercourse in the reference period. Trans-
actional sex was defined as sex in exchange for money, 
gifts or favours. Sex against the will of the participant 
was defined as any episode of being physically forced or 
coerced into sex when this was unwanted. In addition, the 
questionnaire included prevalidated measures of alcohol 
use and dependence.20 Social network size was elicited 
from a sequence of questions yielding the number of 
MSM, over the age of 18 living in Nairobi and met in 
person in the last 2 weeks.
Participants were offered HIV counselling and rapid 
testing following Kenyan HIV Testing Services (HTS) 
guidelines using two commercial rapid diagnostic kits 
(RDT: Determine Alere HIV 1/2 and First Response HIV 
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1–2.0).21 Blood specimens were tested for syphilis (trepo-
nemal haemagglutination (TPHA) and rapid plasma 
reagin (RPR) tests), hepatitis B surface antigen and hepa-
titis C antibody (Mircrowell ELISA, Bios USA) and quali-
tative or quantitative HIV- 1 PCR conditional on rapid test 
results (GeneXpert HIV- 1 Qual or HIV- 1 VL). Urine and 
rectal swabs were collected and tested for Neisseria gonor-
rhoea (NG) and Chlamydia trachomatis (CT) using PCR 
(GeneXpert CTNG).
HIV care continuum measures were based on Centers 
for Disease Control guidelines with a viral suppres-
sion threshold of <50 copies/mL.22 Self- reported HIV 
status awareness and use of ART were collected both by 
computer- assisted survey and as part of HTS. Measures of 
linkage to care within 6 months of diagnosis and reten-
tion in care over the past 12 months were only elicited in 
the survey.
PLWHA not reporting receipt of care were referred to 
government services for initiation of ART. HIV negative 
participants were referred for PrEP eligibility assessment. 
Treatment for other STIs was provided free and according 
to national guidelines. Condoms and water- based lubri-
cants were freely available in the study clinic as was infor-
mation about sexual risk reduction and other GBMSM/
TP- affirming local sexual health services. Participants 
were compensated Ksh500 (~US$5) for completing study 
procedures, as approved by the ethics review board.
Patient and public involvement
Patient and public organisations were involved in the 
design, management and dissemination of the project. 
The original research protocol was developed and 
adapted after consultation with a number of community- 
based organisations representing key populations in 
Nairobi, including the GALCK, HOYMAS, Ishtar MSM 
and the Sex Workers Outreach Programme (SWOP). 
Early in study planning, we submitted draft protocol and 
instruments for consideration of the G10 committee, 
a research sub- committee of GALCK. This resulted in 
the ratification of study objectives from community 
members and multiple improvements to study instru-
ments. The G10 commended the investigators on the 
extent of community consultation conducted in prepa-
ration for the study, including our evidence of Good 
Participatory Practice. The G10 acted as the community 
advisory board for the duration of the study, offering 
prompt feedback on the experience of participants and 
wider perceived threats to study procedures or partici-
pants, such as election disruptions. Staff from HOYMAS, 
Ishtar MSM and SWOP were employed in study roles 
on reception and on social media as service navigators 
for participants seeking services or support outside 
the research. At study closure, we presented research 
findings directly to participants at a public meeting, in 
person and in writing to the boards of all key popula-
tion serving organisations in Nairobi, as well as to formal 
policy- making agencies.
Statistical methods
RDS diagnostics including visualisation of recruitment 
chains, convergence and seed dependence, and statistical 
assessment of recruitment homophily were analysed using 
the rds library for R V.3.4.0.23 24 Crude and sample weighted 
estimates (RDS- II method and excluding seeds)23 of the 
prevalence of sociodemographic and behavioural factors, 
lab- confirmed and self- reported STIs and HIV cascade 
measures (for PLWHA only) are presented in accordance 
with good practice.25 Given evidence of under- reporting 
of status awareness and ART use in HTS and surveys alone 
(see online supplemental material), a composite cascade 
was derived combining both sources and treating any 
report of HIV awareness or treatment receipt as a posi-
tive response. Age and partner count quintiles among 
PLWHA were coded and used throughout for consistency 
Analysis stratified by gender identity has been published 
previously.26
Associations with HIV prevalence in the entire sample, 
and prevalence of detectable HIV viraemia among PLWHA 
only, were assessed using robust Poisson regression with a 
non- clustered sandwich estimator27 for an unbiased esti-
mate of the prevalence ratio.28 Multivariable models were 
specified including sociodemographic (model 1) or full 
(model 2) covariates associated with outcome at p<0.100. 
STIs other than HIV were not included as independent 
covariates in adjusted models given the strong likelihood 
of dependence on behavioural determinants of HIV 
risk. Given the bimodal distribution of viral load among 
PLWHA, comparisons between quantitative VL measures 
were limited to non- parametric significance testing 
(Kruskall- Wallis test) and distribution visualisation (Epan-
echnikov kernels). All analyses of association excluded 
purposively sampled seeds and were not sample weighted 
(given both the known risk of bias in applying network 
weights to multivariate analyses29 and the correlation 
of pertinent behavioural measures with social network 
degree). Less than 5% of covariate measures were missing 
and were included in models as dummy variables. Anal-
yses were performed in Stata V.16.
All participants provided separate written informed 
consent to the questionnaire, sample collection and 
sample storage, and were able to withdraw from any 
portion of the study.
RESULTS
A total of 761 individuals presented to the study site with 
the intention of participation. A total of 124 were ineli-
gible due to fake or missing coupons, repeat attendance, 
intoxication or failure to meet inclusion criteria. Of the 
637 individuals with confirmed eligibility, 29 declined 
participation during consent procedures. Of 608 recruits 
and 10 seeds completing informed consent, one partici-
pant declined blood testing and six declined rectal swabs. 
Four seeds accounted for 516 (84.9%) recruits. Depth of 
recruitment ranged from 1 to 19 waves per seed (median 
7) (online supplemental material).
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Table 1 shows the characteristics of enrolled partic-
ipants. Median age was 24 years (IQR 21–29) with 
38.2% between the ages of 18–22 years. Most partici-
pants reported having attended postprimary education, 
however, a high proportion of participants reported 
being unemployed. A minority of participants reported 
a birthplace outside of Kenya, predominantly in neigh-
bouring East African countries, in particular Uganda 
(n=90). Three- quarters of participants self- identified as 
gay or homosexual, and 15.0% self- identified as non- 
cisgender (predominantly transfeminine or female). 
Only 35.3% (30.9%–39.9%, 229/580) reported having 
been in contact with community- based organisations 
targeting GBMSM/TP during the previous year.
Participants reported a median of two male sexual 
partners in the past 3 months (IQR 1–3). Male partner 
counts were higher among the 44% of participants who 
reported selling sex to men in the past year (median 
3 vs 2 different partners in the last 3 months, Kruskall- 
Wallis p<0.001). Forty- nine per cent (44.5–53.6) reported 
receptive anal intercourse in the past 3 months, of whom 
54.2% (175/321 47.8–60.5) reported at least one episode 
that was condomless. 62.1% (57.6–66.5) reported inser-
tive anal sex with male partners over the same period, of 
whom 44.2% (175/383 38.5–50.0) at least one condom-
less episode. Over a quarter of participants reported 
female sexual partners over that period and participants 
were similarly likely to have sold sex to, or purchased sex 
from, females. A significant proportion of participants 
reported experiencing sex against their will in the last 
12 months. Among HIV negative participants, 59.2% 
(237/396 53.4%–64.6%) reported HIV testing within the 
last 6 months and 4.4% (25/430 2.7%–7.0%) reported 
current oral PrEP use.
A total of 186 participants tested HIV positive (crude 
30.1%, RDS- II 26.4%). Two individuals were positive only 
on PCR testing, representing 2.1% (2/186, 0.5–8.2%) of 
PLWHA or 0.76% (2/426, 0.18–0.30%) of participants 
testing negative by the national RDT algorithm. Five 
participants had evidence of active syphilis infection, 
and hepatitis B and C prevalence was low. Laboratory- 
confirmed rectal STIs were more prevalent than urethral 
STIs, and rectal NG was the most common site- specific 
STI. 82.2% confirmed rectal infections (90/106, 72.0–
89.3%) and 82.3% confirmed urethral infections (49/60, 
68.8–90.8) were asymptomatic on self- report. HIV prev-
alence was crudely associated with prevalent laboratory- 
confirmed rectal NG (PR 2.19 (1.72–2.78), p<0.001), 
rectal CT (PR 1.49 (1.06–2.08), p=0.020) and urethral 
NG (PR 1.92 (1.34–2.75), p<0.001) and with self- reported 
symptoms at rectal (PR 2.37 (1.85–3.05), p<0.001) and 
urethral sites (PR 2.00 (1.49–2.69), p<0.001)
Table 2 shows crude and adjusted variable associa-
tions with HIV status. Across models, increasing age was 
strongly associated with increasing HIV prevalence. In 
fully adjusted models HIV prevalence rose on average 
6.4% per year of age (5.0%–7.9%), p<0.001), from 13% 
among 18–22 years to 48.9% among those over 32 years 







  18–22 225/618 36.4 38.2 (33.8 to 42.8)
  23–26 169/618 27.4 27.2 (23.4 to 31.5)
  27–32 136/618 22.0 20.6 (17.2 to 24.5)
  33+ 88/618 14.2 14.0 (11.1 to 17.5)
Employment
  Salaried (full or 
part time)
179/608 29.4 28.1 (24.1 to 32.4)
  Self employed 159/608 26.2 27.4 (23.5 to 31.8)
  Unemployed 247/608 40.6 41.7 (37.2 to 46.3)
  Other 23/608 3.8 2.9 (1.7 to 4.7)
Education
  Primary 111/611 18.2 18.1 (14.8 to 21.9)
  Secondary 329/611 53.9 55.0 (50.4 to 59.6)
  Higher 171/611 28.0 26.9 (23.0 to 31.1)
Income (Kenya Shillings per month)
  <Ksh5K 224/574 39.0 40.9 (36.2 to 45.7)
  Ksh5K to 
<Ksh10K
166/574 28.9 27.7 (23.6 to 32.1)
  Ksh10K+ 184/574 32.1 31.5 (27.2 to 36.1)
Country of birth
  Kenya 484/607 79.7 78.8 (74.6 to 82.4)
  Other African 
country
112/607 18.5 19.8 (16.3 to 23.9)
  Non- African 
country
11/607 1.8 1.4 (0.7 to 2.9)
Sexual identity
  Gay/homosexual 448/609 73.6 73.2 (69.0 to 77.2)
  Bisexual 143/609 23.5 23.4 (19.7 to 27.6)
  Other 18/609 3.0 3.3 (2.0 to 5.6)
Gender identity
  Cisgender male 522/618 84.5 85.0 (81.5 to 88.0)
  Transfeminine 70/618 11.3 11.3 (8.7 to 14.5)
  Other† 26/618 4.2 3.7 (2.6 to 5.7)
Sexual behaviour—male partners
Male sexual partners (last 3 months)
  None 74/618 12.0 12.5 (9.7 to 15.9)
  1–3 405/618 65.5 72.7 (68.5 to 76.5)
  4 or more 139/618 22.5 14.8 (12.1 to 18.0)
  Sold sex (last 
12 months)
297/613 48.5 43.8 (39.3 to 48.4)
  Paid for sex (last 
12 months)
177/614 28.8 28.2 (24.2 to 32.6)
Anal intercourse with male partner (last 3 months)
  None 77/618 12.5 13.1 (10.2 to 16.5)
  Receptive only 158/618 25.6 24.8 (21.1 to 29.0)
  Insertive only 220/618 35.6 37.9 (33.5 to 42.5)
  Receptive and 
insertive
163/618 26.4 24.2 (20.6 to 28.3)
Continued
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of age. Participants reporting a birthplace outside Kenya 
but within Africa had less than half the HIV prevalence 
of Kenyan- born participants in all models. Transfeminine 
participants had a 50% higher prevalence than cisgender 
GBMSM after adjustment for sociodemographic factors, 
yet not after adjustment for behavioural factors. In crude 
analyses, HIV infection was associated with higher male 
partner counts, selling sex to men and receptive anal 
intercourse. In adjusted models, recent receptive anal 
intercourse was also independently associated with HIV, 
while recent condomless sex with a female partner was 
inversely associated with HIV prevalence.
Figure 1A shows the composite, RDS- II- adjusted care 
cascade among participants with HIV infection (see 
online supplemental material for cascades based on 
survey and HTS measures only). 97.9% (91.8%–99.5%, 
RDS- II, n=184) were detected by the HTS regimen, 76.6% 
(68.2%–83.3%, RDS- II, n=137) reported status aware-
ness and 65.3% (56.6%–73.2%, RDS- II, n=129) reported 
currently receiving ART. 47.4% (38.9%–56.0%), RDS- II, 
n=92) of PLWHA were virally supressed (<50 copies/
mL). Median viral load was highest among two PCR 






Condomless anal intercourse (last 3 
months)
  None 353/618 57.1 58.2 (53.6 to 62.6)
  Receptive only 90/618 14.6 14.4 (11.5 to 18.0)
  Insertive only 90/618 14.6 14.9 (11.9 to 18.5)
  Both 85/618 13.8 12.5 (9.8 to 15.8)




265/618 42.9 41.8 (37.4 to 46.4)
Sexual behaviour—female partners
  Female sexual 
partner (last 3 
months)
174/618 28.2 28.3 (24.4 to 32.7)
  Sold sex to 
female partner 
(last 12 months)
58/615 9.4 9.0 (6.7 to 12.1)
  Paid for sex with 
female partner 
(last 12 months)
67/614 10.9 11.2 (8.6 to 14.6)




94/618 15.2 15.9 (12.8 to 19.6)
Sexual violence
  Forced to have 
sex against will 
(last 12 months)
87/615 14.1 13.1 (10.3 to 16.5)
Substance use 
behaviour
Alcohol use (last 
2 weeks)
  Never 261/618 42.2 45.1 (40.6 to 49.7)
  Monthly 269/618 43.5 42.5 (38.0 to 47.1)
  Weekly 88/618 14.2 12.4 (9.8 to 15.7)
  Other substance 
use (3 m)‡
51/618 8.3 8.0 (5.8 to 10.8)
HIV
  HIV- RNA 
(GeneXpert HIV- 
1 Qual) only
2/617 0.3 0.6 (0.1 to 2.2)
  Rapid test 
(determine/first 
response)
184/617 29.8 25.8 (22.1 to 30.0)
  Total 186/618 30.1 26.4 (22.6 to 30.6)
Syphilis
  Positive (TPHA+ 
/ RPR >3)
5/614 0.8 1.1 (0.4 to 2.8)
Hepatitis B
  Positive hepatitis 
B surface 
antigen (HBsAg)









  Positive anti- 
hepatitis C virus 
antibody (anti- 
HCV Ab)
3/614 0.5 0.4 (0.1 to 1.7)
Rectal STIs
  Lab- confirmed 
rectal N. 
gonorrhoeae
76/611 12.4 13.2 (10.4 to 16.8)
  Lab- confirmed 
rectal C. 
trachomatis
53/611 8.7 8.1 (5.9 to 10.9)
  Self- reported 
rectal STI 
symptoms
51/609 8.4 8.6 (6.3 to 11.6)
Urethral STIs
  Lab- confirmed 
urethral N. 
gonnorhoeae
27/614 4.4 4.4 (2.9 to 6.7)
  Lab- confirmed 
urethral C. 
trachomatis
39/614 6.4 7.3 (5.2 to 10.3)
  Self- reported 
urethral STI 
symptoms
43/601 7.2 6.4 (4.5 to 9.0)
*Seeds dropped and RDS- II weighting.
†‘Other’ includes transmasculine participants and participants not 
currently identifying with the terms male, female or transgender.
‡Ecstacy, amphetimines, mephamphetamine, mephedrone, heroin, 
gamma- hydroxybutyric acid (GHB), rohypnol, cocacine, crack cocaine, 
benzene, amyl nitrite.
RDS, respondent- driven sampling; STIs, sexually transmitted 
infections.
Table 1 Continued
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copies/mL), and declined significantly by each progres-
sive step across the care continuum (figure 1B). Among 
131 participants declaring receipt of HIV care, 61 (41.7 
(31.9–52.2%) last received care in a community organisa-
tion, 44 (36.9% (27.4%–47.6%) in a public hospital, and 
26 (21.5% (14.1%–31.3%) from a private provider.
Factors associated with detectable viraemia among 
PLHWA are shown in table 3. A strong and significant 
inverse trend was apparent between increasing age and 
prevalence of detectable viraemia in both crude and 
adjusted models. On average, the prevalence of detect-
able HIV viraemia decreased by 4.2% per year of age 
(1.8%–6.6%, test for linear trend, p=0.0001). These 
trends were apparent across all metrics of the HIV care 
cascade (figure 2A). Median log viral load among partic-
ipants aged 18–22 was significantly higher than older 
age groups (4.44 vs 1.30 log10 copies/mL, Kruskall- Wallis 
p=0.0012, figure 2B), and both participants with acute 
HIV infections were within this youngest age- group. 
Increasing levels of education attendance were also asso-
ciated with a declining level of viral detection among 
PLWHA, however, this trend was not statistically signifi-
cant. Behavioural correlates of prevalent HIV viraemia 
in the demographically adjusted model (model 1) were 
payment for sex in the last 3 months (with either male or 
female partners) and recent condomless anal intercourse 
with female partners, while there was an inverse associa-
tion with recently selling sex to male partners.
DISCUSSION
Over a quarter of GBMSM and TP in Nairobi now live 
with HIV infection. Our HIV prevalence estimate is 
higher than previous RDS estimates from the same city 
in 2010 (18.2%13) as well as convenience samples else-
where in Kenya (19.8% Malindi 201030; 16.6% Kisumu 
2015).31 Extrapolation of the observed proportion with 
evidence of acute/early HIV infection not detectable by 
fourth generation testing (assuming a conservative esti-
mate of 14- day window period between GeneXpert and 
RDT detection) suggests an annual HIV incident risk of 
15% (4%–58%). Persistently high HIV/STI risk is consis-
tent with high reported levels of known behavioural and 
biological acquisition risks that have not improved over 
time13: over 40% of GBMSM/TP report recent condom-
less anal intercourse and transactional partnerships, and 
a high proportion have concurrent, often asymptomatic, 
STIs. The frequent reports of sex with female partners, 
including transactional sex, among GBMSM is consistent 
with previous research in Kenya, as is the lower observed 
HIV risk among bisexually active as opposed to exclusive 
GBMSM likely due to differences in role behaviour and 
network prevalence.32 Antiretroviral prevention uptake 
remains poor for these populations and while the national 
PrEP programme was in the process of deployment 
during this study, subsequent evaluation since confirms 
inadequate uptake and persistence among GBMSM/TP.33
However, this study does highlight significant progress 
in reaching key populations with HIV testing and care. 
We estimate that three- quarters of GBMSM/TP living with 
HIV in Nairobi are aware of their status and nearly half 
have been supported to achieve viral suppression, anal-
ogous to 77- 85- 73 against UNAIDS targets. This cascade 
compares favourably to collated GMSM/TP cascade 
data from elsewhere in sub- Saharan Africa (18- 53- 76)9 
Figure 1 (A) Diagnosis and care cascade among GBMSM/TP living with HIV. *Kenyan National HIV testing algorithm: Serial 
Determine Alere and First Response Rapid Diagnostic Tests. Point estimates are RDS adjusted and exclude seeds. Error bars 
represent 95% CIs. (B) Log viral load median and distribution by level of diagnosis and care cascade engagement. Intervals: 
(A, B) HIV positive only on GeneXpert; (B, C) HIV positive on RDT but participant not status aware; (C, D)—Participant reports 
status awareness but reports no current use of ART; (D) Participants reports current use of ART. Vertical bars represent IQR, 
white dots represent median log viral load. Median and category sample size stated in label. <LLD: (40 copies/mm3). P values 
from Kruskall- Wallis equality of populations rank test. ART, antiretroviral therapy; GBMSM/TP, gay, bisexual and other men who 
have sex with men/transgender persons; LLD, lower limit of detection; PLWHA, persons living with HIV/AIDS; RDS, respondent- 
driven sampling.
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as well as to that reported in global self- reported surveys 
(NA- 82–58).34 This is by no means a small achieve-
ment of HIV programming within a societal context of 
homophobic discrimination and criminalisation of same 
sex behaviour6 and represents marked improvements in 
access to HIV care that will directly translate into better 
health outcomes for GBMSM and TP living with HIV. 
However, cascades fall behind those for PLWH in the 
Kenyan general population (80- 96- 91 in 2017)12 and for 
GBMSM and transgender in high- income settings.35
There is increasing evidence demonstrating the effec-
tiveness of mHealth36 37 and other social media interven-
tions38 on testing uptake and linkage to HIV services for 
GBMSM, while effects on retention and care outcomes 
are as yet inconclusive. Internet based interventions may 
be highly suited to the context of this study since internet 
services and social media are widely accessible and utilised 
among these populations.39 However, any such inter-
vention requires cautious adaptation and testing given 
associated risks arising from disclosure these services 
that has also been reported in this context. LINKAGES 
recommend peer navigation strategies as an element of 
core HIV- related interventions for key populations,40 yet 
such strategies remain underused in Kenyan key popu-
lation programmes despite local evidence of the effec-
tiveness of this approach on care outcomes.41 Most of the 
community- based organisations serving GBMSM/TP in 
Nairobi already use various models of peer outreach for 
client engagement, and the addition of quality assured 
peer navigation could be both complementary and 
impactful.
Inequalities in coverage of HIV diagnosis and care for 
persons living with HIV were principally driven by age. We 
observed strong positive associations between increasing 
age and virological suppression, as well as other metrics 
of the care cascade. Median viral load was 3.14 log higher 
among participants age 18–22 living with HIV than older 
GMSM/TP (4.44 v 1.30 respectively, p=0.0022), reflecting 
both lower status awareness and care engagement in 
addition to higher HIV incident risk in the youngest 
age group. The observation that HIV prevalence was 
13% among GBMSM/TP aged 18–22 years suggests that 
risk begins earlier in adolescence when prevention and 
care may be even less accessible. Although comparable 
evidence is scarce from elsewhere in sub Saharan Africa, 
Ramadhani reported higher HIV risk behaviour and inci-
dence, yet lower healthcare engagement, status awareness 
and virological suppression among Nigerian GBMSM/TP 
aged 16–19 years.42
The WHO highlight the need for national responses 
to be acceptable to young key populations,43 and our 
findings suggest a focus on GBMSM/TP youth is overdue 
and will be essential to the overall success of Kenyan 
key population HIV response. Improving accessibility to 
youth may require redress of structural barriers to service 
access, such as age- based consent criteria, training of staff 
to recognise additional needs of young GBMSM/TP, but 
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of key populations will be sceptical of the confidenti-
ality and safety of healthcare settings.44 Pettifor proposes 
that services for adolescent and young MSM need to be 
targeted and holistic, given the complex and concurrent 
challenges of conceptualising HIV risk and prevention 
during a period of personal biological and psychological 
change, and often alongside stressors related to accep-
tance and disclosure of sexual or gender identity to family 
and friends.44 Effective interventions targeting HIV 
prevention and care engagement among young MSM 
have mostly been tested in the USA, and offer supportive 
evidence for both digital interventions on testing uptake45 
and peer- based network support interventions to support 
retention.46 Adaptation and demonstration of accept-
ability of interventions to young GBMSM/TP in highly 
stigmatised contexts should be a priority.
Our findings also suggest that improved diagnostics 
could complement both HIV prevention and care for 
GBMSM/TP in Nairobi. A small but significant propor-
tion of GBMSM/TP were identified with prevalent acute/
early HIV infection accompanied by high viral loads, and 
undetected by current national testing practices. In addi-
tion, we found a high proportion of GBMSM/TP with 
asymptomatic, urethral and rectal STIs, well recognised 
as a cofactor in HIV transmission.47 Laboratory capacity 
for STI diagnosis remains limited and expensive in 
Kenya, therefore most providers, especially community- 
based organisations, rely solely on syndromic manage-
ment. Our findings concur with others in suggesting such 
approaches alone have unacceptably poor diagnostic 
performance.48 49 The decreasing complexity and cost of 
point- of- care PCR technologies should encourage policy- 
makers to re- evaluate the cost- effectiveness of providing 
access to PCR- based HIV and STI diagnostics particularly 
in community settings.50
A key strength of the study was the population repre-
sentative design that avoids many of the biases intrinsic 
to studies conducted solely among GBMSM/TP already 
engaged with research programs or service providers. 
RDS diagnostics suggest convergence on all main demo-
graphic measures, and these measures compared closely 
to a previous study of the same design in Nairobi.13 The 
complex steps required to demonstrate eligibility for 
inclusion in coupon- referral studies might have presented 
obstacles to legitimate study access for some genuine 
coupon recipients, and our inclusion criteria might also 
have limited participation for important subpopulations, 
such as persons who inject drugs or harmful alcohol 
users. Limitations of the study include the cross- sectional 
design (precluding examination of causal direction of 
correlates) and the reliance on self- reported measures of 
behaviours and service uptake that are potentially subject 
to memory error and social desirability bias. Foremost 
among these was differential under- reporting of status 
awareness and antiretroviral use in surveys and with care 
providers. This phenomenon has been reported by other 
population- based studies, has the potential to significantly 
distort interpretation of cascade measures and under-
scores the need for verification of self- reported measures 
wherever possible.51 52
In summary, coverage of HIV care for GBMSM and TP 
living with HIV in Nairobi is close to that achieved in the 
general population and reflects the inclusive approach 
of the national HIV/AIDS strategy in Kenya. However, 
ending AIDS for key populations demands even better 
access to care, a re- energised PrEP response, and access 
to relevant HIV and STI diagnostics available wherever 
GBMSM/TP feel safe seeking these services. Going 
forward policy- makers must now seek to understand and 
address the specific sexual health service preferences 
of adolescent and younger key populations in order to 
address age- related inequalities in access to diagnosis and 
care.
Author affiliations
1Nuffield Department of Population Health, University of Oxford, Oxford, UK
Figure 2 (A) HIV care cascade measures by age group. Point estimates are unadjusted for sampling strategy and exclude 
seeds. Error bars represent 95% CIs. (B) Log viral load median and distribution by age group. Vertical bars represent IQR, white 
dots represent median viral load (also stated in label). <LLD: (40 copies/mm3). ART, antiretroviral therapy; LLD, lower limit of 
detection; PLWHA, persons living with HIV/AIDS.









pen: first published as 10.1136/bm






13Smith AD, et al. BMJ Open 2021;11:e055783. doi:10.1136/bmjopen-2021-055783
Open access
2Department of Social and Environmental Health Research, London School of 
Hygiene and Tropical Medicine, London, UK
3Partners for Health and Development, Nairobi, Kenya
4Department of Global Health & Development, London School of Hygiene & Tropical 
Medicine, London, UK
5Sigma Research, London School of Hygiene & Tropical Medicine, London, UK
6Australian Research Centre in Sex, Health and Society, La Trobe University, 
Melbourne, Victoria, Australia
7Department of Global Health & Development, Partners for Health and Development, 
Nairobi, Kenya
8Department of Community Health Sciences, University of Manitoba, Winnipeg, 
Manitoba, Canada
Twitter Peter Weatherburn @#PeterWea
Acknowledgements We would like to acknowledge and thank the commitment of 
study participants, and are grateful to our community partner organisations: the Gay 
and Lesbian Coalition of Kenya (GALCK); Ishtar MSM and Health Options for Young 
Men with AIDS (HOYMAS) for their support of study procedures and in dissemination 
of findings. We thank our administrative, counselling, clinical and laboratory staff at 
the TRANSFORM clinic and Partners for Health and Development for Africa (PHDA) 
for their hard work and dedication.
Contributors AS contributed to designing the study and data collection 
instruments, carried out quantitative analyses and wrote the first draft of the 
manuscript; AB contributed to conceiving and designing the study and data 
collection instruments and drafting of the manuscript; JK and RK contributed to 
designing the study and data collection instruments, implementation of study 
procedures and commented on the manuscript. EI, MK, PM, HB and CN contributed 
to the implementation and operation of study procedures. PW and EF contributed 
to conceiving and designing the study and data collection instruments and 
commented on the manuscript. All authors approved the final draft. JK acts as the 
guarantor.
Funding This work was supported by Evidence for HIV Prevention in Southern 
Africa (EHPSA) award number MM/EHPSA/WHC/0116029.
Competing interests None declared.
Patient consent for publication Not applicable.
Ethics approval This study was approved by the Kenya Medical Research Institute 
Scientific and Ethics Review Unit (KERMI/SERU/CGMR- C/CSC 044/3334), the 
University of Oxford, Oxford Tropical Research Ethics Committee (OxTREC 47- 16) 
and London School of Hygiene and Tropical Medicine Human Research Ethics 
Committee (REF: 14144).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available on reasonable request. Data 
from this study have not been deposited publicly because of the potential risk of 
deductive disclosure that may arise from individual data needed for valid analysis 
of the data, and the potential individual and social harms that may arise from such 
disclosure in a context of criminalisation and stigmatisation. However, all authors 
aim to make the data underlying the findings of the study available for legitimate 
research purposes, and requests will be considered by the London School of 
Hygiene and Tropical Medicine Research Operations Office Data Management lead ( 
alex. hollander@ lshtm. ac. uk). The request must specify the purpose of research, the 
list of required variables, and if personally identifiers or sensitive data are sought, 
specify measures to maintain information security and governance that will be 
applied in storage, handling and reporting the data.
Supplemental material This content has been supplied by the author(s). It 
has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have 
been peer- reviewed. Any opinions or recommendations discussed are solely 
those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability 
and responsibility arising from any reliance placed on the content. Where the 
content includes any translated material, BMJ does not warrant the accuracy and 
reliability of the translations (including but not limited to local regulations, clinical 
guidelines, terminology, drug names and drug dosages), and is not responsible 
for any error and/or omissions arising from translation and adaptation or 
otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 




 1 Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology 
of HIV infection in men who have sex with men. Lancet 
2012;380:367–77.
 2 Baral SD, Poteat T, Strömdahl S, et al. Worldwide burden of HIV in 
transgender women: a systematic review and meta- analysis. Lancet 
Infect Dis 2013;13:214–22.
 3 Poteat T, Scheim A, Xavier J, et al. Global epidemiology of HIV 
infection and related syndemics affecting transgender people. J 
Acquir Immune Defic Syndr 2016;72:S210–9.
 4 Poteat T, Ackerman B, Diouf D, et al. HIV prevalence and behavioral 
and psychosocial factors among transgender women and cisgender 
men who have sex with men in 8 African countries: a cross- sectional 
analysis. PLoS Med 2017;14:e1002422.
 5 Smith AD, Tapsoba P, Peshu N, et al. Men who have sex with men 
and HIV/AIDS in sub- Saharan Africa. Lancet 2009;374:416–22.
 6 Pew Research Center. The global divide on homosexuality persists. 
Pew Research Center, 2020.
 7 UNAIDS. The gap report. Geneva: UNAIDS, 2014.
 8 Risher K, Mayer KH, Beyrer C. HIV treatment cascade in MSM, 
people who inject drugs, and sex workers. Curr Opin HIV AIDS 
2015;10:420–9.
 9 Stannah J, Dale E, Elmes J. Sub- optimal engagement of African 
MSM in the HIV treatment cascade: a systematic review and meta- 
analysis HIV R4P. Madrid, Spain 2018.
 10 Gupta S, Granich R. National HIV care continua for key populations. 
J Int Assoc Provid AIDS Care 2017;16:125–32.
 11 Mwau M, Syeunda CA, Adhiambo M, et al. Scale- up of Kenya’s 
national HIV viral load program: findings and lessons learned. PLoS 
One 2018;13:e0190659.
 12 National AIDS and STI Control Programme. KENPHIA 2018 
preliminary report. Nairobi: NASCOP, 2020.
 13 Muraguri N, Tun W, Okal J, et al. HIV and STI prevalence and risk 
factors among male sex workers and other men who have sex with 
men in Nairobi, Kenya. J Acquir Immune Defic Syndr 2015;68:91–6.
 14 Kunzweiler CP, Bailey RC, Mehta SD, et al. Factors associated with 
viral suppression among HIV- positive Kenyan gay and bisexual men 
who have sex with men. AIDS Care 2018;30:S76–88.
 15 Ministry of Health, National AIDS and STI Control Programme. 
Guidelines on the use of anti- retroviral drugs for treating and 
preventing HIV infection in Kenya. Nairobi, Kenya: Ministry of Health, 
2016.
 16 WHO. Consolidated Guidlines on HIV prevention, diagnosis, 
treatment and care for key populations: 2016 update. Geneva, 
Switzerland: WHO, 2016.
 17 Heckathorn DD. Respondent- driven sampling: a new approach to 
the study of hidden populations. Soc Probl 1997;44:174–99.
 18 Lyons C, Stahlman S, Holland C, et al. Stigma and outness about 
sexual behaviors among cisgender men who have sex with men and 
transgender women in Eswatini: a latent class analysis. BMC Infect 
Dis 2019;19:211.
 19 Stahlman S, Hargreaves JR, Sprague L, et al. Measuring sexual 
behavior stigma to inform effective HIV prevention and treatment 
programs for key populations. JMIR Public Health Surveill 
2017;3:e23.
 20 Babor T, Higgins- Biddle J, Saunders J. AUDIT: the alcohol use 
disorders identification test. In: Guidlines for use in primary care. 2nd 
edn. Geneva: WHO, 2001.
 21 National AIDS and STI Control Programme. Guidelines for HIV testing 
services in Kenya. Nairobi, Kenya: Government of Kenya, 2015.
 22 Centers for Disease Control. Understanding the HIV care continuum. 
Atlanta, Georgia: Division of HIV/AIDS Preventon, National Center for 
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, 2017.
 23 Handcock MS, Fellows IE, Gile KJ. RDS: respondent- driven 
sampling, 2012. Available: https://CRAN.R-project.org/package=RDS 
[Accessed 30 Oct 2020].
 24 Gile KJ, Johnston LG, Salganik MJ. Diagnostics for respondent- 
driven sampling. J R Stat Soc Ser A Stat Soc 2015;178:241–69.
 25 Volz E, Heckathorn DD. Probability based estimation theory for 
respondent driven sampling. J Offic Stat 2008;24:79–97.
 26 Smith AD, Kimani J, Kabuti R, et al. HIV burden and correlates of 
infection among transfeminine people and cisgender men who have 









pen: first published as 10.1136/bm






14 Smith AD, et al. BMJ Open 2021;11:e055783. doi:10.1136/bmjopen-2021-055783
Open access 
sex with men in Nairobi, Kenya: an observational study. Lancet HIV 
2021;8:e274–83.
 27 Huber PJ. The behvior of maximum likelihood estimates under non- 
standard conditions. Berkeley, CA: University of California Press, 
1967.
 28 Barros AJD, Hirakata VN. Alternatives for logistic regression in cross- 
sectional studies: an empirical comparison of models that directly 
estimate the prevalence ratio. BMC Med Res Methodol 2003;3:21.
 29 Avery L, Rotondi N, McKnight C, et al. Unweighted regression 
models perform better than weighted regression techniques for 
respondent- driven sampling data: results from a simulation study. 
BMC Med Res Methodol 2019;19:202.
 30 Singh K, Brodish P, Mbai F, et al. A venue- based approach to 
reaching MSM, IDUs and the general population with VCT: a three 
study site in Kenya. AIDS Behav 2012;16:818–28.
 31 Sandfort TGM, Dominguez K, Kayange N, et al. HIV testing and the 
HIV care continuum among sub- Saharan African men who have sex 
with men and transgender women screened for participation in HPTN 
075. PLoS One 2019;14:e0217501.
 32 Smith AD, Muhaari AD, Agwanda C, et al. Heterosexual behaviours 
among men who sell sex to men in coastal Kenya. AIDS 
2015;29:S201–10.
 33 Were D, Musau A, Mutegi J, et al. Using a HIV prevention cascade 
for identifying missed opportunities in PrEP delivery in Kenya: 
results from a programmatic surveillance study. J Int AIDS Soc 
2020;23:e25537.
 34 Ayala G, Makofane K, Santos G- M. Hiv treatment cascades that leak: 
correlates of drop- off from the HIV care continuum among men who 
have sex with men worldwide. J AIDS Clin Res 2014;05.
 35 O'Halloran C, Sun S, Nash S. HIV in the United Kingdom: towards 
zero 2030. London: Public Health England, 2019.
 36 Muessig KE, LeGrand S, Horvath KJ, et al. Recent mobile health 
interventions to support medication adherence among HIV- positive 
MSM. Curr Opin HIV AIDS 2017;12:432–41.
 37 Nelson KM, Perry NS, Horvath KJ, et al. A systematic review of 
mHealth interventions for HIV prevention and treatment among gay, 
bisexual, and other men who have sex with men. Transl Behav Med 
2020;10:1211–20.
 38 Cao B, Gupta S, Wang J, et al. Social media interventions to promote 
HIV testing, linkage, adherence, and retention: systematic review and 
meta- analysis. J Med Internet Res 2017;19:e394.
 39 Fearon E, Bourne A, Tenza S, et al. Online socializing among men 
who have sex with men and transgender people in Nairobi and 
Johannesburg and implications for public health- related research 
and health promotion: an analysis of qualitative and respondent- 
driven sampling survey data. J Int AIDS Soc 2020;23:e25603.
 40 LINKAGES. Peer navigation for key populations: implementation 
guide: FHI 360. LINKAGES, 2017.
 41 Graham SM, Micheni M, Chirro O, et al. A randomized controlled 
trial of the Shikamana intervention to promote antiretroviral therapy 
adherence among gay, bisexual, and other men who have sex with 
men in Kenya: feasibility, acceptability, safety and initial effect size. 
AIDS Behav 2020;24:2206–19.
 42 Ramadhani HO, Crowell TA, Nowak RG, et al. Association of age 
with healthcare needs and engagement among Nigerian men who 
have sex with men and transgender women: cross- sectional and 
longitudinal analyses from an observational cohort. J Int AIDS Soc 
2020;23:e25599.
 43 Baggaley R, Armstrong A, Dodd Z, et al. Young key populations 
and HIV: a special emphasis and consideration in the new who 
consolidated guidelines on HIV prevention, diagnosis, treatment and 
care for key populations. J Int AIDS Soc 2015;18:19438.
 44 Pettifor A, Stoner M, Pike C, et al. Adolescent lives matter: 
preventing HIV in adolescents. Curr Opin HIV AIDS 
2018;13:265–73.
 45 Bauermeister JA, Pingel ES, Jadwin- Cakmak L, et al. Acceptability 
and preliminary efficacy of a tailored online HIV/STI testing 
intervention for young men who have sex with men: the get 
connected! program. AIDS Behav 2015;19:1860–74.
 46 Bouris A, Jaffe K, Eavou R, et al. Project nGage: results of a 
randomized controlled trial of a Dyadic network support intervention 
to retain young black men who have sex with men in HIV care. AIDS 
Behav 2017;21:3618–29.
 47 Bernstein KT, Marcus JL, Nieri G, et al. Rectal gonorrhea and 
chlamydia reinfection is associated with increased risk of HIV 
seroconversion. J Acquir Immune Defic Syndr 2010;53:537–43.
 48 Sanders EJ, Thiong'o AN, Okuku HS, et al. High prevalence of 
Chlamydia trachomatis and Neisseria gonorrhoeae infections among 
HIV- 1 negative men who have sex with men in coastal Kenya. Sex 
Transm Infect 2010;86:440–1.
 49 Shah NS, Kim E, de Maria Hernández Ayala F, et al. Performance 
and comparison of self- reported STI symptoms among high- risk 
populations - MSM, sex workers, persons living with HIV/AIDS - in El 
Salvador. Int J STD AIDS 2014;25:984–91.
 50 Palmer S, Dijkstra M, Ket JC, et al. Acute and early HIV infection 
screening among men who have sex with men, a systematic review 
and meta- analysis. J Int AIDS Soc 2020;23:e25590.
 51 Fogel JM, Sandfort T, Zhang Y, et al. Accuracy of self- reported HIV 
status among African men and transgender women who have sex 
with men who were screened for participation in a research study: 
HPTN 075. AIDS Behav 2019;23:289–94.
 52 Mooney AC, Campbell CK, Ratlhagana M- J, et al. Beyond social 
desirability bias: investigating inconsistencies in self- reported HIV 
testing and treatment behaviors among HIV- positive adults in North 
West Province, South Africa. AIDS Behav 2018;22:2368–79.









pen: first published as 10.1136/bm






1: Respondent Driven Sampling recruitment diagnostics 
 
In line with guidance1 we conducted monitoring of the RDS recruitment every two weeks 
and made recommendations to the data collection team on the basis of findings. We 
examined RDS recruitment trees, return of coupons, assessed sample composition by 
sociodemographic characteristics, and examined convergence on key outcomes overall and 




Waves and seeds 
Ten seed participants recruited a total of 608 participants, though 512/608, 84% of all 
participants, came from 4 seeds of between 14 and 19 waves, Table A1. The largest 
recruitment chain of Seed 1 recruited 143/608 (23.5%) of participants, whilst Seed 3 had the 
largest number of recruitment waves, Table A2.  
 
Table A1: Number of participants recruited by wave 
 
Wave 0 1 2 3 4 5 6 7 8 9 10 11 12 
No. Participants 10 19 29 43 57 69 80 64 66 49 37 29 24 
 
Wave 13 14 15 16 17 18 19 
No. Participants 12 12 4 6 6 1 1 
 
Table A2: Number of participants and recruitment waves recruited via each seed 
 
Seed Number of participants (%) Waves 
1 143 (23.5%) 17 
2 17 (2.8%) 6 
3 139 (22.9%) 19 
4 139 (22.9%) 15 
5 39 (6.4%) 8 
6 4 (0.7%) 2 
7 91 (15.0%) 14 
8 22 (3.6%) 6 
9 2 (0.3%) 1 
10 12 (2.1%) 4 
 
Coupon receipt 
96.9% of participants received a coupon from a close friend or friend. Only 2 (0.4%) of 
participants reported that they received their coupon from a stranger, which violates the 
RDS assumption that participants receive a coupon from someone within their social 
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network (and the recruitment instructions). Consistent with whom they received a coupon 
from, the majority of participants reported that they received it from or near their home. 
There were 17 participants (2.8%) who reported receiving their coupon outside the study 
clinic which could imply distributions to individuals who just happened to be passing rather 
than distribution to an individual’s social network, but this is not certain.  
 
A minority of 45/600 (7.5%) of participants reported that they had received more than one 
offer of a coupon, which suggests that recruitment did not get stuck within a small group 
trying to recruit each other and did not saturate the target population. 
 
Table A3: Characteristics of coupon receipt reported by participants 
 
 n % 
Relationship to person from whom received coupon (n=576)   
Close friend 292 50.7 
Friend 266 46.2 
Acquaintance 14 2.4 
Stranger 2 0.4 
Other 2 0.4 
   
Where received coupon (n=598)   
At/near home 301 50.3 
At/near work 76 12.7 
On street 86 14.4 
Bar/club 96 16.1 
Outside the study clinic 17 2.8 
Other 22 3.7 
   
Apart from the person who gave you the coupon you brought today has 
anyone else tried to give you a coupon? (n=600)   
No 555 92.5 
Yes 45 7.5 
How many times?   
1 19 48.7 
2 15 38.5 
4 1 2.6 
5 2 5.1 
7 1 2.6 
11 1 2.6 
 
 
Convergence of Estimates  
Each convergence plot shows the cumulative RDS-II weighted proportion of the population 
estimate as the sample recruitment progressed. We examined key sociodemographic 
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Figure A2  
a. Age: proportion 25 years or more e. Gender identity 
  
b. Educational attendance f. HIV: proportion positive 
 
 
c. Employment g. Viral suppression: proportion of PLWHA 
  
d. Sexual identity  
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Bottlenecks 
We show the bottleneck plot for basic demographic features only to limit the potential for 
deductive disclosure of seed identity. 
 
Figure A3a. Age: proportion 25 years or more 
 
Figure A3b. Educational attendance: proportion attended higher education 
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Figure A3c. Current employment: proportion unemployed 
 
 
Whilst the sample achieved equilibrium on age (Figure A2a) and the trajectory of individual 
recruitment chains were heading for convergence, there was some evidence for persisting 
seed dependence in recruitment by age throughout the study. One recruitment chain, the 
longest (orange), tended to have a slightly higher proportion of those aged 25 years and 
over compared to other long recruitment chains (green & purple, Figure A3a), consistent 
with evidence of recruitment homophily by age (Table 1). The fourth longest chain (pink) 
tended to have a higher proportion of those aged under 25, perhaps also consistent with a 
lower proportion of those reporting attendance in higher education (Figure A3b). However 
convergence on educational attendance was achieved for the sample as a whole. Similarly, 
current employment converged for across the whole sample for each employment category, 
with no evidence of seed dependence in the proportion unemployed by recruitment chain 
(Figure A3c) 
 
The cumulative weighted estimated proportion of different self-identified sexual identities 
did not appear to vary greatly by recruitment chain (not shown), and convergence was 
achieved on the overall sample albeit slightly later in recruitment than for demographic 
variables. Conversely there was some evidence that the cumulative proportion of 
transfeminine participants was still increasing as the study closed (Figure A2e), accounted 
for by a consistently higher proportion of transfeminine recruits in one of the larger 
recruitment chains active at the end of the study (not shown). 
 
With respect to HIV outcomes, the cumulative proportion of HIV positive participants 
appeared to have stabilised at slightly lower weighted proportion until late in recruitment 
and at the end of recruitment the weighted HIV prevalence was rising slightly (Figure A2f).  
The proportion of those living with HIV who were virologically suppressed reached 
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equilibrium early in the study, yet also rose slightly very late in recruitment. Whilst there 
was no evidence for seed dependence in bottleneck plots in cumulative HIV prevalence, 
convergence of one recruitment with previously low HIV prevalence did not occur until late 
in recruitment, and this particular recruitment chain had a systematically higher proportion 
of persons living with HIV who had achieved virological suppression (not shown).  
 
Recruitment Homophily  
Recruitment homophily (the ratio of number of recruits that have the same characteristic as 
their recruiter to the number we would expect if there was no homophily) was assessed for 
key demographic and outcome variables (Table 1). The strongest evidence of preferential 
recruitment of recruits with similar characteristics of the recruiter was for age and HIV 
status, in both cases suggesting that recruiters were more likely to identify recruits from the 
same age group or HIV status. With respect to age, this concurs with reported origin of most 
recruits from within friendship networks which can be anticipated to be assortative. The 
modest indication of homophily by HIV status might reflect either overlaps of identification 
of recruits from sexual, rather than social, networks (thus non-independent of the recruiters 
HIV status), or alternatively recruitment through networks formed around HIV care or 
prevention services. 
 
Table 1: Recruitment homophily estimates 
Characteristic Homophily estimate Х2 test for independence (p) 
Age group 1.36 3.58 x 10-10 
Educational attendance 1.07 0.295 
Current Employment 1.08 0.0724 
Sexual identity 1.00 0.0364 
Gender identity 1.00 0.8593 
HIV status 1.16 6.02 x 10-9 




The majority of participants reported that they knew the person who had given them a 
coupon, a key assumption of the RDS method (mutuality). With the exception of two seeds 
who recruited less than five participants, a satisfactory number of sample waves was 
achieved. The demographic characteristics of the achieved sample appeared to converge 
convincingly by the end of recruitment, however convergence of self-identified sexuality 
occurred later and gender identity may not have reached equilibrium within our sample 
size. In the absence of recruitment homophily by these factors, this suggests some seed 
dependence due to segregation of social and sexual networks by these factors rather than 
by recruitment preferences. Primary outcome estimates (HIV status and viral suppression 
amongst those HIV-positive) appeared to converge reasonably, although we noted minor 
deviations from equilibrium late in recruitment. Our observations of increases in both HIV 
positive status as well as proportion virologically suppressed late into recruitment, as well as 
modest recruitment homophily by HIV status, suggest preferential recruitment by factors 
related to the receipt of HIV care later in the study, such as higher age. However this may 
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have reflected difficulties in recruitment through social activities or perceived risks in 
attending central Nairobi locations during civil disruption related to election disputes that 
occurred late in the study and close to the study site2.  
 
The mean age of participants was quite young: 77% of our RDS sample were <30 years of 
age, compared to 45% <30 years of age in the wider Nairobi population3. This sampling bias 
has been observed in other RDS surveys of MSM adults in sub-Saharan Africa4, and is 
thought to reflect age and cohort effects in MSM socialising patterns as well as relative 
difficulties in reaching older MSM/TG in many parts of the region5. The sample was also 
slightly different to the only previous RDS study of MSM in Nairobi6: the 2010 sample was 
somewhat older (56.5% <30 years), less likely to report post-primary education than the 
TRANSFORM sample, yet were similarly likely to report sex work. It is unclear whether these 
differences represent changes in the demographics of MSM/TP populations over the 
interim, or reflect differences in RDS performance. Whilst diagnostics are not available for 
Muraguri et al), the vast majority of recruits were derived from one seed. 
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Viral load suppression cutoff 
 Disclosed awareness 
of living with HIV 
Disclosed current use 
of ART 
<1000 copies/ml <200 copies/ml <50 copies/ml 
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3: Survey tool 
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TRANSFORM English Survey Instrument 
SA Version 4 | KENYA version 1.4 dated 06/02/2017 
 
1 
TRANSFORM Survey Instrument v.4 
 
 
Date today:   [year/months/day]  
 
Site name:    _______________ 
 
Study Staff name:   _______________ 
 
Participant ID number:  _______________ 
 
Thank you for agreeing to complete this survey. We will now ask you a few questions about yourself. Please remember 
that you do not have to answer any questions you do not want to answer and you can stop the survey at any time.  
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TRANSFORM English Survey Instrument 




There are three main types of questions .. the most common has small ROUND buttons for the answers 
and you can click only one answer. Once you have clicked on an answer the question will disappear and the 
next one will be shown. If you have made a mistake, just click the left-facing arrow head ("BACK") button 
on the bottom left hand side of the screen. Try this one ... 
 
How handsome are you? 
 Handsome 
 Very handsome 
 Incredibly handsome 
 
Other questions have small SQUARE buttons for the answers and you can click as many of the answers as 
you like. Once you have clicked on an answer the question will not dissappear - when you have finished 
you need to click the right-facing arrow head ("NEXT") button on the bottom right hand side. If you have 
made a mistake, just click the left-facing arrow head ("BACK") button on the bottom left hand side. Try this 
one ... 
 
Which of the following sports do you watch on television? 
Notice these questions often have an "OTHER" option - if you click this you need to type in your other 
answer. Click "OTHER" and write in "Boxing" (or any other sport you watch). 
 Soccer 
 Rugby 
 Cricket  
 Other – please say which: (type in) 
 
A few questions ask you when you last did something and offer you a calender to pick the exact day, 
month and year. When this happens you can navigate the months and years using the left and right arrows 
on the calendar. When you have picked you date for your answer, click "Set" to record it. Once you have 
clicked on "Set" the question will disappear and the next one will be shown. Try this one ... 
 
When did you last speak to one of your family members? 
 Select date (day, month, year)  
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AX. Coupon management 
We are now going to start the survey properly - please answer every question honestly. Please remember that you do 
not have to answer any questions you do not want to answer and you can stop the survey at any time. All your 
responses are totally confidential.  
 
The first set of questions are about how you found out about the study, and where you got the coupon.  
 






Q1a, If Q1 = Other ask, How else do you know them? 
[write in] 
 
AX2. Where were you when you received a coupon to participate in the study? 
At or near home 
At or near work 
Out and about on the street 
At a bar/club 
Outside this office 
Elsewhere (say where ____________) 
 
AX3. If you had participated in the survey first, do you think that you might have given a coupon to the person who 
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TRANSFORM English Survey Instrument 




A. QUESTIONS ABOUT YOU (1) 
The first set of questions are about you .. your age, where you live, and where you were born, for example. The survey 
has started - all your answers are confidential. Please answer questions truthfully.  
 
A1. How old are you? 
_____ (years) 
 
A2. Which neighbourhood do you live in? 









Other (please specify) ____________ 
 










Other (please specify) ____________ 
 
A3. Were you born in [Kenya / South Africa]? 
No 
Yes [jump to A5] 
 




A4a. [If A4 is yes] Which country in Africa were you born? 
  [Select from list of countries] 
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A6. [If A5 is no] Which town  were you born in? 
Town/Village ____________ 
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A. QUESTIONS ABOUT YOU (2) 
A8. What is your highest level of education completed? 
[SHOW IF SOUTH AFRICA]  
No education 
Primary school 
Junior high school 
High school or technical secondary school 
College, university or higher education 
 




College, university or higher education 
 




Unemployed or between jobs 
Other (say what____________) 
 
 
A11. What was your income last month? 
[SHOW IF KENYA]  
KSH [enter number] 
 
[SHOW IF SOUTH AFRICA]  
ZAR [enter number]  
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A. QUESTIONS ABOUT YOU (3) 












 Prefer not to say 
 Other 
 





Other (please say what ____________) 
Don’t know 
 








Other (please say what _____________) 
 
A16. What sex were you assigned at birth (e.g. on your original birth certificate)? 
Male 
Female 
Prefer not to answer 
 




I do not identify as male, female or transgender 
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TRANSFORM English Survey Instrument 




A18. What is your current marital status? 
Married / civil union / legal partnership 
Single/divorced/widowed [SKIP TO NEXT SECTION] 
 




Other – say what 
 
B. SOCIAL: FRIENDSHIPS 
We now want you to answer some questions about other men who have sex with men (MSM) who you know. 
 
B1. How many other MSM do you know whom you have had a conversation with in the past month? By ‘know’, we mean 
someone who knows your name and you know theirs, and by 'had a conversation with', we mean either in person, on 
the phone, using SMS or online. 
[enter number] 
 
B2. How many of these [B5] men know each other? 
  All or almost all of them know each other  
  Most of them know each other [around <ROUND[B5*.75]> of them] 
  About half of them know each other [around <ROUND[B5*.5]> of them] 
  Some, but not the majority, know each other [around <ROUND[B5*.25]> of them]  
  Very few or none of them know each other  
 
B3. How many of these [B1] men have you met in person? 
[enter number] 
 
B4. How many of these [B3] men are 18 years of age or older? 
[enter number] 
 
B5. How many of these [B4] men live in the same city as you? 
[enter number] 
 
B6. How many of these [B5] men have you seen in the past two weeks? 
[enter number] 
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The next set of questions asks about how you meet and socialise with other men that have sex with men. 
 
B8. When did you last visit any of these places to socialise with other MSM? 
 Visited in the 
last month 
Visited in the 
last year, but 
not in last 
month 
Visited more 




Outdoor meeting place e.g. the park, the 
street, the beach 
⃝ ⃝ ⃝ ⃝ 
Bar or club ⃝ ⃝ ⃝ ⃝ 
Private house e.g. your house or a 
friends house 
⃝ ⃝ ⃝ ⃝ 
Sauna, bathhouse or sex party ⃝ ⃝ ⃝ ⃝ 
Community space for MSM e.g. drop in 
centre, MSM organisation facilities 
⃝ ⃝ ⃝ ⃝ 
 
B9. When did you last use a website or mobile app to socialise with other MSM? 
Never [jump to B12] 
In the last month 
In the last year 
More than one year ago 
 
B10. Which of the following internet services have you used to socialise with MSM in the last month [tick all that 
apply]? 
2go ⃝ Facebook ⃝ Hornet ⃝   
Adam4Adam ⃝     Radar ⃝ 
  Gay Radar  ⃝ Instagram ⃝ Red Velvet ⃝ 
  Gay.com ⃝ iPlay ⃝ Scruff ⃝ 
Badoo ⃝ Gaydar ⃝   Sex Trader South Africa ⃝ 
      Skype ⃝ 
  Gayxchange ⃝ Mambaonline ⃝ Snapchat ⃝ 
  Get Male ⃝ Manhunt ⃝   
  Grindr ⃝   Twitter  ⃝ 
    ManToManPlus ⃝ Twoo ⃝ 
Dating Buzz ⃝ Guy Spy ⃝ Men2Men ⃝ WeChat ⃝ 
      Whatsapp ⃝ 
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  Hookups ⃝ Planet Romeo ⃝   
B11. On the 1st January this year, were you registered as a user of the following services? 
 






B11.b. Planet Romeo 
  Yes 
  No  
 
B11.c. Hornet 
  Yes 
  No 
 
[SHOW IF COUNTRY=SOUTH AFRICA] 
 
B11.d. Mamba Online 
  Yes 
  No 
 
[If yes to B11a] B11.e. On January 1st this year, how many profiles do you have on Grindr? 
  [Enter number] 
 
[If yes to B11b] B11.f. On January 1st this year, how many profiles do you have on Planet Romeo? 
  [Enter number] 
 
[If yes to B11c] B11.f. On January 1st this year, how many profiles do you have on Hornet? 
  [Enter number] 
 
[If yes to B11d] B11.g.On January 1st this year, how many profiles do you have on Mambo Online? 
  [Enter number] 
 
 
B12. Have you ever visited or received information from a community organisation or support group for men who 
have sex with men? 
No [JUMP TO NEXT SECTION] 
Yes 
Don’t know/not sure [JUMP TO NEXT SECTION] 
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B13. Which of the following gay/LGBT organisations or support groups have you VISITED in the past year? 
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C. SOCIAL SUPPORT 
The next set of questions are about social support - or how much support you get from any partner/s, 
friends and family. 
 














C1. There is a special person who is around when I am in need 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C2. There is a special person with whom I can share joys and sorrows 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C3. My family really tries to help me 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C4. I get the emotional help & support I need from my family 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C5. I have a special person who is a real source of comfort to me 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C6. My friends really try to help me 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C7. I can count on my friends when things go wrong 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C8. I can talk about my problems with my family 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C9. I have friends with whom I can share my joys and sorrows 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C10. There is a special person in my life who cares about my feelings 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C11. My family is willing to help me make decisions 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C12. I can talk about my problems with my friends 
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 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
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D. SOCIAL: DISCLOSURE & DISCRIMINATION DUE TO SEXUALITY 
The next set of questions are about telling people about having sex with other men and any problems this might have 
caused you. 
Please play close attention to the questions in this section. Some ask you to think about the last 12 months, while 
others ask you to think about your whole life (ever). 
 




D2. Have you ever felt that family members have made discriminatory remarks or gossiped about you because you 




D3. In general, do you try to keep it hidden from your FAMILY that you have sex with men? 
I try very hard to hide it 
Try somewhat to hide it 
I don’t try to hide it, but I don’t talk about it 
I openly talk about it 
Not applicable 
 
D4. In general, do you try to keep it hidden from your FRIENDS that you have sex with men? 
I try very hard to hide it 
Try somewhat to hide it 
I don’t try to hide it, but I don’t talk about it 
I openly talk about it 
Not applicable 
 




D6. In general, do you try to keep it hidden from HEALTH CARE WORKERS that you have sex with men? 
I try very hard to hide it 
Try somewhat to hide it 
I don’t try to hide it, but I don’t talk about it 
I openly talk about it 
Not applicable 
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D7. In the last 12 months, have you felt afraid to go to health care services because you worry someone may learn 




D8. In the last 12 months, have you avoided going to health care services because you worry someone may learn 




D9. In the last 12 months, have you felt that you were not treated well in a health centre because someone knew 




D10. In the last 12 months, have you heard health care providers gossiping or laughing about you because you have 
















D17. In the last 12 months, has someone ever physically hurt you (pushed, shoved, slapped, hit, kicked, choked or 
otherwise physically hurt you) due to the fact that you have sex with men? 
Yes 
No [JUMP TO D20] 
 
D18. Who did this? [Tick all that apply] 
A stranger 
A family member 
A member of the police or a public official 
A health provider 
A partner 
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A sex client 
Other 
 
D20. In the last 12 months, have you been forced to have sex when you did not want to? (By forced, we mean 
physically forced, coerced to have sex, or penetrated with an object, when you did not want to) due to the fact that 
you have sex with men? 
Yes 
No [JUMP TO D24]  
 
 
D21. Who did this? [Tick all that apply] 
A stranger 
A family member 
A member of the police or a public official 
A health provider 
A partner 
A sex client 
Other 
 
D24. In the last 12 months, have you been threatened with detention or arrest by a member of the police or public 
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E. SEXUAL BEHAVIOUR 
We would now like to ask you about your recent sexual behaviour. By sex we mean any genital contact - including 
masturbation (wanking, fingering); oral sex (sucking/blowjobs, licking, rimming); vaginal or anal intercourse (fucking). 
 
E1. In the last 3 months, have you had sex with a man? 
  Yes  
  No 
 
E1a. [If E1 = yes ] How many different men have you had sex with in the last 3 months? 
[Enter number]  
 
E2. In the last 3 months, what type of anal sex have you engaged in with men? 
Receptive anal sex only (‘bottom’) 
Insertive anal sex only (‘top’) 
Both receptive and insertive anal sex (versatile) 
None of the above 
 
E3 [if E2= receptive or both] In the last 3 months, how often did you use condoms when you were the receptive 
partner / were bottom for anal sex? 
Always 
Most of the time 




E4. [if E2= Insertive or both] In the last 3 months, how often did you use condoms when you were the insertive 
partner / were top for anal sex? 
Always 
Most of the time 




E5. In the last 3 months, what type of oral sex have you engaged in with men?  
Receptive oral sex only (I gave a blow job) 
Insertive oral sex only (I was sucked off) 
Both ways  
None of the above 
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E6. In the last 12 months, have any men paid you in return for sex? By payment we mean he gave you money, gifts 




E7. In the last 12 months, have you paid a man in return for sex with him? By payment we mean you gave him 
money, gifts or favours in return for sex. 
Yes 
No 
E8. In the last 12 months, have any of your male partners every tried to hurt you? By this we mean pushing, 
holding you down, hitting you with his fist, kicking, attempting to strangle, attacking with a knife, gun or other 
weapon 
  Yes 
  No 
 
E9. In the last 12 months, have any of your male partners used physical force or verbal threats to force you to 
have sex when you did not want to? 
  Yes 
  No 
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E10. In the last 3 months have you had sex with a woman? 
  Yes  
  No [JUMP TO NEXT SECTION] 
 
E10a. How many women have you had sex with in the 3 months?  
[enter number]  
 






E12. [if E11= vaginal or both] In the last 3 months, how often did you use condoms when you had vaginal sex with 
a female partner? 
Always 
Most of the time 




E13 [if E11=anal or both] In the last 3 months, how often did you use condoms when you had anal sex with a 
female partner? 
Always 
Most of the time 




E14. In the last 12 months, have any women paid you in return for sex? By payment we mean she gave you 




E15. In the last 12 months, have you paid a woman in return for sex with her? By payment we mean you gave her 
money, gifts or favours in return for sex. 
Yes 
No 
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EX. SEXUAL BEHAVIOUR: PARTNERSHIP DYADS 
 
We now want you to think about the last FOUR people you had sex with. We want to ask you a set of questions about 
each of these FOUR people. Choose a nickname or set of initials to help identify each one. These do not need to be 
real nicknames or initials, just something that will help keep track of who we are asking about.  
Remember that by sex we mean any genital contact - including masturbation (wanking, fingering); oral sex 
(sucking/blowjobs, licking, rimming); vaginal or anal intercourse (fucking). 
 
Partner #1: 
Who was the last person you had sex with? (Write in a nickname, first name or initials)  
[Enter initials] 
 
Partner # 2: 
Before (Partner #1) who was the last person you had sex with? (Write in a nickname, first name or initials)
 [Enter initials] 
 
Partner #3: 
Before (Partner #2) who was the last person you had sex with? (Write in a nickname, first name or initials)
 [Enter initials] 
 
Partner #4: 
Before (Partner #3) who was the last person you had sex with? (Write in a nickname, first name or initials)
 [Enter initials] 
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The following set of questions are about the first partner you mentioned. 
 
ROUTE 1: A CASUAL, ONE-OFF SEXUAL PARTNER 
 
What is the most recent date [closest to today] you had sex with [partner #1]? Please make your best guess if you 
cannot remember exactly. 
[enter date] 
 
What is the gender of [partner #1] 
  Male 
  Female 
  Transgender 
  Don’t know 
 
How old was [partner #1] when you last had sex with them? Please make your best guess if you are unsure. 
  [enter age] 
 





At a bar or club 
At a private party 
On a social networking site - say which one  
  Other - say where you met 
I don’t remember 
 
How many times have you ever had sex with [partner #1] 
  Only once 
  More than once 
 
Do you expect to have sex with [partner #1] again in the future? 
Yes  
There are three main routes through this section of the survey, depending on whether they are (1) a casual, one-off 
partner, (2) a regular sexual partner who they expect to have sex with again in the future, and (3) a partner who was 
regular but who they do not expect to have sex with again in the future. The online survey hosting system will 
automatically route people through the survey based on prior responses. For this Word version, all three routes are 
presented in turn. Revisions were necessary to this section following piloting. The questions remain largely the same 
as our previous submission, but have been re-ordered for clarity of completion and in anticipation of multiple partner 
types.  
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Did you give [partner #1] money, gifts or favours in exchange for sex with you? 
  No 
  Yes 
 
Did [partner #1] give you money, gifts or favours in exchange for sex with you? 
  No 
  Yes 
 
EX28[i] [if EX3=male]  
What type of sex have you ever had with [Partner #1]? [tick all that apply] 
  Receptive anal sex (I was bottom) 
  Insertive anal sex (I was top) 
  Receptive oral sex (I gave a blow job) 
  Insertive oral sex (I was sucked off) 
 
EX29A[i] [if EX3=male & EX28 = receptive anal sex]  
When you had receptive anal sex / was bottom with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
 
EX29B[i] [if EX3=male & EX28 = insertive anal sex]  
When you had insertive anal sex / was top with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
 
EX30[i] [if EX3=female]  
What type of sex have you ever had with [Partner #1]? [tick all that apply] 
  Vaginal sex 
  Anal sex 
  Oral sex 
 
EX31A[i] [if EX3= female & EX28 = vaginal sex] 
When you had vaginal sex with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
 
 
EX31B[i] [if EX3= female & EX28 = anal sex]  
Last time you had anal sex with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
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EX33[i] Has [Partner #1] shared his/her HIV status with you? 
No [JUMP TO E35[i]] 
Yes 
I do not know 
 
EX34[i] What is [Partner #1]’s HIV status?  
HIV-positive [they had HIV infection] 
HIV-negative [they did not have HIV infection] 
I do not know 
 
SKIP TO E36[i] 
 
EX35[i] What did you believe [Partner #1]’s HIV status to be at the time you had sex with them? 
  I think HIV-positive 
  I think HIV-negative 
  I do not know 
  
 
ROUTE 2: A REGULAR SEXUAL PARTNER WHO THEY EXPECT TO HAVE SEX WITH AGAIN IN THE FUTURE 
 
 
What is the most recent date [closest to today] you had sex with [partner #1]? Please make your best guess if you 
cannot remember exactly. 
[enter date] 
 
What is the gender of [partner #1] 
  Male 
  Female 
  Transgender 
  Don’t know 
 
How old was [partner #1] when you last had sex with them? Please make your best guess if you are unsure. 
  [enter age] 
 





At a bar or club 
At a private party 
On a social networking site - say which one  
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  Other - say where you met 
I don’t remember 
 
How many times have you ever had sex with [partner #1] 
  Only once 
  More than once 
 




EX20A[i] [if EX19i=YES] Which of the following best describes your current relationship with <EX1[i]>? 
  We are married / in a civil partnership with each other  
  We are going steady / regular partners (i.e. long term boyfriend or girlfriend) 
  We are friends who occasionally have sex 
  We just meet for sex  
 
EX21A[i] [if EX19i=YES] Do you live with them? 
  Yes 
  No 
 
EX22A[i] [if EX19i=YES] Are you in love with <EX1[i]>? 
  Yes, very much 
  Yes, a little 
  No 
 
EX24A[i] [if EX19i=YES] Are you dependent on <EX1[i]> for income, money or somewhere to stay? 
  Yes, very much 
  Yes, a little 
  No 
 
EX26[i]. Do you give them money, gifts or favours in exchange for sex with you? 
  No 
  Yes 
 
EX27[i]. Do they give you money, gifts or favours in exchange for sex with you? 
  No 
  Yes 
 
EX28[i] [if EX3=male]  
What type of sex have you ever had with [Partner #1]? [tick all that apply] 
  Receptive anal sex (I was bottom) 
  Insertive anal sex (I was top) 
  Receptive oral sex (I gave a blow job) 
  Insertive oral sex (I was sucked off) 
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EX29A[i] [if EX3=male & EX28 = receptive anal sex]  
Last time you had receptive anal sex / was bottom with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
 
EX29B[i] [if EX3=male & EX28 = insertive anal sex]  
Last time you had insertive anal sex / was top with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
 
EX30[i] [if EX3=female]  
What type of sex have you ever had with [Partner #1]? [tick all that apply] 
  Vaginal sex 
  Anal sex 
  Oral sex 
 
EX31A[i] [if EX3= female & EX28 = vaginal sex] 
Last time you had vaginal sex with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
 
 
EX31B[i] [if EX3= female & EX28 = anal sex]  
Last time you had anal sex with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
 
EX33[i] Has [Partner #1] shared his/her HIV status with you? 
No [JUMP TO E35[i]] 
Yes 
I do not know 
 
EX34[i] What is [Partner #1]’s HIV status?  
HIV-positive [they had HIV infection] 
HIV-negative [they did not have HIV infection] 
I do not know 
 
SKIP TO E36[i] 
 
EX35[i] What do you believe [Partner #1]’s HIV status to be? 
  I think HIV-positive 
  I think HIV-negative 
  I do not know 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-055783:e055783. 11 2021;BMJ Open, et al. Smith AD
 
TRANSFORM English Survey Instrument 
SA Version 4 | KENYA version 1.4 dated 06/02/2017 
 
26 
EX36[i] Have you and [Partner #1] ever accompanied each other to any of the following [check any that apply] 
Counselling and testing for HIV 
Appointment at a sexual health clinic 
Appointment at an HIV treatment clinic 
A health information session or event for MSM 
Attended a social event arranged by an MSM organisation 
  NO, none of the above 
 
 
ROUTE 3: A FORMERLY REGULAR SEXUAL PARTNER WHO THEY DO NOT EXPECT TO HAVE SEX WITH AGAIN IN THE 
FUTURE 
 
What is the most recent date [closest to today] you had sex with [partner #1]? Please make your best guess if you 
cannot remember exactly. 
[enter date] 
 
What is the gender of [partner #1] 
  Male 
  Female 
  Transgender 
  Don’t know 
 
How old was [partner #1] when you last had sex with them? Please make your best guess if you are unsure. 
  [enter age] 
 





At a bar or club 
At a private party 
On a social networking site - say which one  
  Other - say where you met 
I don’t remember 
 
How many times have you ever had sex with [partner #1] 
  Only once 
  More than once 
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EX20B[i] [if EX19i=NO] Which of the following best describes the relationship you had with <EX1[i]>? 
  We were married / in a civil partnership with each other 
  We were going steady / regular partners (i.e. long term boyfriend or girlfriend) 
  We were friends who occasionally had sex 
  We just met for sex  
 
EX21B[i] [if EX19i=NO & EX18i=YES] When you were in a relationship, did you live with <EX1[i]>? 
  Yes 
  No 
 
EX22B[i] [if EX19i=NO & EX18i=YES] When you were in a relationship, were you in love with <EX1[i]>? 
  Yes, very much 
  Yes, a little 
  No 
 
EX24B[i] [if EX19i=NO] Were you dependent on <EX1[i]> for income, money or somewhere to stay? 
  Yes, very much 
  Yes, a little 
  No 
 
EX26[i]. Did you give them money, gifts or favours in exchange for sex with you? 
  No 
  Yes 
 
EX27[i]. Did they give you money, gifts or favours in exchange for sex with you? 
  No 
  Yes 
 
EX28[i] [if EX3=male]  
What type of sex have you ever had with [Partner #1]? [tick all that apply] 
  Receptive anal sex (I was bottom) 
  Insertive anal sex (I was top) 
  Receptive oral sex (I gave a blow job) 
  Insertive oral sex (I was sucked off) 
 
EX29A[i] [if EX3=male & EX28 = receptive anal sex]  
Last time you had receptive anal sex / was bottom with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
 
EX29B[i] [if EX3=male & EX28 = insertive anal sex]  
Last time you had insertive anal sex / was top with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
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EX30[i] [if EX3=female]  
What type of sex have you ever had with [Partner #1]? [tick all that apply] 
  Vaginal sex 
  Anal sex 
  Oral sex 
 
EX31A[i] [if EX3= female & EX28 = vaginal sex] 
Last time you had vaginal sex with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
 
EX31B[i] [if EX3= female & EX28 = anal sex]  
Last time you had anal sex with [Partner #1], was this with or without a condom? 
  With a condom 
  Without a condom 
 
EX33[i] Has [Partner #1] shared his/her HIV status with you? 
No [JUMP TO E35[i]] 
Yes 
I do not know 
 
EX34[i] What is [Partner #1]’s HIV status?  
HIV-positive [they had HIV infection] 
HIV-negative [they did not have HIV infection] 
I do not know 
 
SKIP TO E36[i] 
 
EX35[i] What did you believe [Partner #1]’s HIV status to be when you last had sex with them? 
  I think HIV-positive 
  I think HIV-negative 
  I do not know 
  
EX36[i] Have you and [Partner #1] ever accompanied each other to any of the following [check any that apply] 
Counselling and testing for HIV 
Appointment at a sexual health clinic 
Appointment at an HIV treatment clinic 
A health information session or event for MSM 
Attended a social event arranged by an MSM organisation 
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To finish off this set we are going to ask you a few questions about whether any of the partners you just described 
know each other. 
 
 
EX37 [IF >1 MALE] As far as you know, are any of these men sexually active with each other, as well as with you? 
Yes 
No [SKIP TO NEXT SECTION] 
I don’t know [SKIP TO NEXT SECTION] 
 
EX38 [IF >1 MALE REPORTED] Please indicate which men are sexually active with each other 
<EX1> & <EX2> [IF BOTH MALE] 
<EX1> & <EX3> [IF BOTH MALE] 
<EX1> & <EX4> [IF BOTH MALE] 
<EX2> & <EX3> [IF BOTH MALE] 
<EX2> & <EX4> [IF BOTH MALE] 
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F. KNOWLEDGE & SELF EFFICACY REGARDING HIV & SEXUAL HEALTH 
The next set of questions are about what you know about HIV and how easy you find it to manage your sexual health. 
 
F1. The following statements are all TRUE. Did you know this already?  
F1a. ‘Effective treatment of HIV infection reduces the risk of HIV being transmitted’ 
I knew this already 
I wasn’t sure about this 
I didn’t know this already 
I don’t understand this 
 
F1b. ‘It is possible to catch HIV during anal sex with a man’ 
I knew this already 
I wasn’t sure about this 
I didn’t know this already 
I don’t understand this 
 
F1c. ‘It is possible to catch HIV even when you are the active partner (the ‘top’) during anal sex’ 
I knew this already 
I wasn’t sure about this 
I didn’t know this already 
I don’t understand this 
 
F2. To what extent do you agree with the following statements? 
 
Strongly disagree Mildly disagree Neutral Mildly agree Strongly agree 
F2a. ‘The sex I have is always as safe as I want it to be’ 
 ⃝ ⃝ ⃝ ⃝ ⃝ 
F2b. ‘I can ensure condoms are used with a sexual partner if I want them to be used’ 
 ⃝ ⃝ ⃝ ⃝ ⃝ 
F2c. ‘I sometimes have a problem getting condoms when I need them’ 
 ⃝ ⃝ ⃝ ⃝ ⃝ 
F2d. ‘I sometimes have problems with condoms that do not fit properly’ 
 ⃝ ⃝ ⃝ ⃝ ⃝ 
F2e. ‘I sometimes have a problem getting water-based lubricant when I need it’ 
 ⃝ ⃝ ⃝ ⃝ ⃝ 
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G. SEXUAL HEALTH & HIV 
The next set of questions are about testing for HIV. 
 
G1. What do you believe your current HIV status is today? 
Negative (I do not think I have HIV) 
Positive (I think I have HIV) 
Not sure 
 
G2. Have you ever taken an HIV test? 
Yes 
No [jump to section G PART III] 
 
G3: In what month and year was your most recent HIV test? 
[enter date MM/YYYY] 
 
 
G4: Where did you take your most recent HIV test? 
Public hospital or clinic 
Private hospital or clinic 
Community HIV testing service for the public 
Community HIV testing service for MSM only 
A place where I meet my friends (bar or club) 
At home  
Other [please specify] 
 
G5. When you took your last HIV test, were you satisfied with the privacy of the service? 




I don't remember / I did not think about it 
 
G7. When you took your last HIV test, were you satisfied with the respect staff showed you? 




I don't remember / I did not think about it 
 
G8. What was the result of your most recent HIV test?  
Negative (I did not have HIV at my last test) 
Positive (I have HIV)  
I don’t know 
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SECTION G PART I: ABOUT BEING HIV POSITIVE  
The next set of questions are about having diagnosed HIV. 
 
G10. In what month and year were you first diagnosed HIV positive? 
[enter date MMYY] 
 
G11. When you were first diagnosed HIV positive, were you referred to a health care provider about your HIV 
infection or HIV related health? By ‘health care provider’ we mean a clinic at which you might see a doctor or clinical 




G12. Since you were first diagnosed HIV positive, have you ever visited a health care provider about your HIV 
infection or HIV related health? 




G13 Why did you not visit the health care provider after having been referred to them? (tick any that apply) 
Negative attitude of clinic staff toward MSM 
Negative attitude of clinic staff toward people living with HIV 
Fear of being noticed going to the clinic 
Long distance to get to the clinic 
High cost of the clinic/tests 
High cost of travel to the clinic 
High cost of medication 
Fear of medication side effects 
Fear that my medication will be noticed  
Did not believe the medication would work 
Did not believe I needed the medication 
Other reason [please specify_______________] 
 
G14. From the date that you learnt you were HIV positive, how soon did you first see a health care provider for HIV 
care? 
On the same day as I learned my status 
Within 2 weeks of learning my status 
2 to 4 weeks after learning my status 
1 to 3 months after learning my status 
3 to 12 months after learning my status 
Over one year after learning my status 
ADDED Never seen health care provider about my HIV 
 
G15. Where did you go the first time you visited a health care provider for this purpose? 
A public hospital or clinic 
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A private hospital or clinic 
A clinic just for men who have sex with men 
 
ROUTINE HIV CARE 
The next set of questions is about routine HIV care and support. 
 
G16. When did you last see a health professional about your HIV care?  
Within the last 6 months 
Between 6 to 12 months ago 
Between 1 to 2 years ago 
More than 2 years ago 
 
G17. Where did you go the last time you visited a health care provider for this purpose? 
A public hospital or clinic 
A private hospital or clinic 
A clinic just for men who have sex with men 
 
G18. The last time you visited a health care provider for HIV care, were you satisfied with the privacy of the service? 
Very satisfied  
Satisfied  
Dissatisfied  
Very dissatisfied  
I don't remember / I did not think about it 
 
G20. The last time you visited a health care provider for HIV care, were you satisfied with the respect staff showed 
you? 




I don't remember / I did not think about it 
 
G22. Have you ever received a test to see how well your immune system is functioning. This is called a CD4 test? 
  Yes 
  No 
  Not sure 
 
G22a. [If G22 = yes] When did you last receive a CD4 count test result? 
Within the last 6 months 
Between 6 to 12 months ago 
Between 1 to 2 years ago 
More than 2 years ago 
 
G23. [If G22 = yes] What was your CD4 count the last time this was tested? 
More than 500 
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I was told the result, but I do not remember 
I was told the result, but I did not understand it 
I was not told the result 
 
G24. Have you ever received a test to measure the amount of HIV infection in your blood? This is called a viral 
load test.  
  Yes 
  No 
  Not sure 
 
G24a. [If G24 = yes] When did you last receive a viral load test result? 
Within the last 6 months 
Between 6 to 12 months ago 
Between 1 to 2 years ago 
More than 2 years ago 
 
G25. [If G24 = yes] What was the result of your viral load the last time it was tested? 
Undetectable 
Detectable 
I was told the result, but I do not remember 
I was told the result, but I did not understand it 
I was not told the viral load test result 
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HIV TREATMENT (ART) 
The next set of questions is about taking anti-HIV treatments (ART, HAART). 
 
G26. Have you ever started taking antiretroviral therapy (sometimes called ART or HAART) for your HIV infection? 
Yes 
No [JUMP TO G28] 
 
G27. You have said you first learned of your HIV infection in <G8 MM YY>. How soon after this did you start ART?  
On the same day as I learned my status 
Within 2 weeks after learning my status 
2 to 4 weeks after learning my status 
1 to 3 months after learning my status 
3 to 12 months after learning my status 
Over one year after learning my status 
[JUMP TO SECTION G PART IV] 
 
G28. Has your healthcare provider suggested you start antiretroviral treatment (ART)?  
Yes 
No [JUMP TO SECTION G PART IV] 
 
G29. What factors made you decide not to start antiretroviral treatment (ART)? [Tick all that apply] 
Negative attitude of clinic staff toward MSM 
Negative attitude of clinic staff toward people living with HIV 
Fear of being noticed going to the clinic 
Long distance to get to the clinic 
High cost of the clinic/tests 
High cost of travel to the clinic 
High cost of medication 
Fear of medication side effects 
Fear that my medication will be noticed  
Did not believe the medication would work 
Did not believe I needed the medication 
Other reason [please specify_______________] 
 
 [JUMP TO SECTION G PART IV] 
 




[If G30 = no] When did you stop taking antiretroviral treatment (ART)? 
Within the last 6 months 
Between 6 to 12 months ago 
Between 1 to 2 years ago 
More than 2 years ago 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-055783:e055783. 11 2021;BMJ Open, et al. Smith AD
 
TRANSFORM English Survey Instrument 




[If G30 = no] G32. What factors made you decide to stop taking antiretroviral treatment? [Tick all that apply] 
Negative attitude of clinic staff toward MSM 
Negative attitude of clinic staff toward people living with HIV 
Fear of being noticed going to the clinic 
Long distance to get to the clinic 
High cost of the clinic/tests 
High cost of travel to the clinic 
High cost of medication 
Fear of medication side effects 
Fear that my medication will be noticed  
Did not believe the medication was working 
Did not believe I needed the medication any more 
Other reason [please specify_______________] 
 
[If G30 = yes] G31. Many patients find it difficult to take all of their HIV medication exactly as prescribed. How many 
doses of your HIV medication did you miss in the last 7 days? 
   
  [Enter number of doses] 
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SECTION G PART II: ABOUT BEING HIV NEGATIVE 
 
The next set of questions is about testing negative for HIV. 
 
G33. In the last 12 months, how many times have you taken an HIV test? 
[enter a number] 
  
G34. If you decided to take an HIV test again, where would you prefer to do the test?  
  Public hospital or clinic 
  Private hospital or clinic 
  Community HIV testing service for the public 
  Community HIV testing service for MSM only 
  A place where I meet my friends (e.g. bars or clubs) 
  At home  
 
G35. If you decided to take an HIV test again, who would you prefer to perform the test? 
Doctor or clinical officer 
Nurse 
Counsellor 
MSM community worker  
Me [i.e. self-test] 
 
[JUMP TO SECTION G PART IV] 
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SECTION G PART III: ABOUT NEVER TESTING FOR HIV 
 
The next set of questions are about never having tested for HIV. 
 
G36. Please give any reasons why you  never tested for HIV before? 
  [enter text] 
It is not important to me to know 
I expect I have the same status as my partner 
I do not know where to get tested  
I may not be treated with respect at the clinic 
I am afraid that I might have HIV  
I am afraid of being treated differently if I take a test  
I am afraid of being treated differently if I have HIV  
It would cause problems in my relationship  
I have no reason to think I have HIV  
Other reason (say what______________) 
 
G37. How confident are you that you could get a test for HIV if you wanted one in the future?  
Very confident  
Quite confident  
A little confident  
Not at all confident  
I don't know 
 
G38. If you decided to take an HIV test in the future, where would you prefer to do the test?  
  Public hospital or clinic 
  Private hospital or clinic 
  Community HIV testing service for the public 
  Community HIV testing service for men who have sex with men only 
  A place where I meet my friends (e.g. bars or clubs) 
  At home  
 
G39. If you decided to take an HIV test in the future, who would you prefer to perform the test? 
Doctor or clinical officer 
Nurse 
Counsellor 
MSM community worker  
Me [i.e. self-test] 
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SECTION G PART IV: OTHER SEXUALLY TRANSMITTED INFECTIONS 
 
The next set of questions are about the symptoms of certain sexually transmitted infections. 
 
G40. In the last 12 months, have you had a discharge from the penis or pain when you pass urine? 
Yes 
No [JUMP to G42] 
 




G42. In the last 12 months, have you had a discharge from the anus or severe pain during anal sex? 
Yes 
No [JUMP to G44] 
 




G44. In the last 12 months, have you noticed any sores on the penis or around the anus?  
Yes 
No 
[IF A16 = A17 PAST TO NEXT SECTION] 
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SECTION G PART V: TRANSGENDER SEXUAL HEALTH ACCESS 
 
IF DISCREPENCY BETWEEN ANSWER TO A16 AND A17, OR IF TRANS IDENTIFYING IN A17 
 
The next of questions is about access to - and use of - transgender services. 
 
G45. How confident are you that you could access counselling concerning your gender? 
Very confident  
Quite confident  
A little confident  
Not at all confident  
I don't know 
 
G46. Do you currently use hormone or hormone-blocking therapies? 
  Yes 
  No [SKIP TO G48] 
 
G47. From where do you access these therapies? 
  Public hospital or clinic 
  Private hospital or clinic 
  Purchased directly from a pharmacy 
  Purchased over the internet 
Obtained from friends 
[SKIP TO G49] 
 
G48. How confident are you that you could access hormone or hormone-blocking therapies in <COUNTRY> if you 
wanted them? 
Very confident  
Quite confident  
A little confident  
Not at all confident  
I don't know 
 
G49. Have you had any surgery related to your gender  [PILOT: REQUIRES ACCEPTABLE & UNDERSTANDABLE LOCAL 
TERM]? 
  Yes 
  No [SKIP TO G51] 
 
G50. Where were you able to access these services? 
  Public hospital in this country 
  Private hospital in this country 
  Hospital in another country 
[JUMP TO NEXT SECTION] 
 
G51. How confident are you that you could access surgery related to your gender 
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Very confident  
Quite confident  
A little confident  
Not at all confident  
I don't know 
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H. Post Exposure Prophylaxis (PEP)  
The next set of questions is about Post Exposure Prophylaxis - which is also known as PEP. 
 
H1. The following statement is true. Did you know this already? 
Post exposure prophylaxis (PEP) is a one-month course of pills that may stop someone from becoming infected with 
HIV if they are exposed to the virus (such as by having sex without condoms). PEP needs to be started as soon as possible 
AFTER an HIV risk. 
 
I knew this already 
I wasn’t sure about this 
I didn’t know this already 
I don’t understand this 
 










H4. [If yes to H3] For how many days did you take PEP? (If you’ve taken it more than once, think about the last time 
you took it) 
[enter number]  
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H. Pre Exposure Prophylaxis (PrEP)  
The next set of questions is about Pre Exposure Prophylaxis - which is also known as PrEP. 
 
H6. The following statement is true. Did you know this already? 
Pre exposure prophylaxis (PrEP) involves someone who does not have HIV taking a pill on an on-going basis to prevent 
them getting HIV. Most people who use PrEP take a pill everyday. PrEP needs to be taken BEFORE sex for it to be 
effective. 
I knew this already 
I wasn’t sure about this 
I didn’t know this already 
I don’t understand this 
 
PrEP is different from PEP. PEP is taken AFTER a risk and PrEP is taken BEFORE.  
 
H7. Have you ever tried to get PrEP? 
Yes 
No [JUMP TO H10] 
Don’t know [JUMP TO H10] 
 
H8. Have you ever been offered PrEP? 
  Yes 
  No 
  Not sure/don’t know 
 
H8. Have you ever taken PrEP? 
Yes, and I am still using it  
Yes, but I stopped taking it  
No [JUMP TO H10] 
Don’t know [JUMP TO H10] 
 
H9. Where did you access your PrEP?  
A doctor at a public hospital or clinic 
A doctor at a private hospital or clinic 
At a community based organization 
From a dedicated website (say which one) 
Somewhere else (say where) 
 
[JUMP TO NEXT SECTION] 
 
H10. [IF G1 = NEGATIVE or NOT SURE] If PrEP was made available to you how likely do you think that you would use 
it?  
Very likely 
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Not sure  
Not very likely  
Very unlikely  
 
H11. If PrEP was made available to you, where would you prefer to access it? [Tick one] 
At a public hospital or clinic 
At a private hospital or clinic 
At a community based organization 
From a pharmacy 
From a dedicated website 
Somewhere else (say where) 
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SECTION I. ALCOHOL USE 
The next set of questions are about drinking alcohol. 
 
I1. How often do you have a drink containing alcohol? 
Never 
Monthly 
2-4 times a month 
   2-3 times a week 
4 or more times a week 
 
I2. How many drinks containing alcohol do you have on a typical day when you are drinking? 
1 or 2 
3 or 4 
5 or 6 
7 to 9 
10 or more 
 
I3. How often do you have six or more drinks on one occasion? 
Never 
Less than monthly 
Monthly 
Weekly 
Daily or almost daily 
 
I4. How often during the last year have you found that you were not able to stop drinking once you had started? 
Never 
Less than monthly 
Monthly 
Weekly 
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Daily or almost daily 
 
I5. How often during the last year have you failed to do what was normally expected of you because of drinking? 
Never 
Less than monthly 
Monthly 
Weekly 
Daily or almost daily 
 
I6. How often during the last year have you needed a first drink in the morning to get yourself going after a heavy 
drinking session? 
Never 
Less than monthly 
Monthly 
Weekly 
Daily or almost daily 
 
I7. How often during the last year have you had a feeling of guilt or remorse after drinking? 
Never 
Less than monthly 
Monthly 
Weekly 
Daily or almost daily 
 
I8. How often during the last year have you been unable to remember what happened that night before because of 
your drinking? 
Never 
Less than monthly 
Monthly 
Weekly 
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Daily or almost daily 
 
I9. Have you or someone else been injured because of your drinking? 
No 
Yes, but not in the last year 
Yes, during the last year 
 
I10. Has a relative, friend, doctor or other health care worker been concerned about your drinking or suggested you 
cut down? 
No 
Yes, but not in the last year 
Yes, during the last year  
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SECTION J. SUBSTANCE USE 
The next set of questions are about your use of tobacco and other drugs ... 
 
J1. Please indicate when you have used any of the following substances: 
Substance Never Within the last 
month 
Within the last 
year but not the 
last month 
More than 
one year ago 
Tobacco ⃝ ⃝ ⃝ ⃝ 
Cannabis (grass, weed, herb, ndom, 
bhang, ganja, dagga, zol) 
⃝ ⃝ ⃝ ⃝ 
Khat (miraa, veve, mogoka) ⃝ ⃝ ⃝ ⃝ 
Ecstasy (E, umgwinyo, happy pill, disco 
biscuit, Adam) 
⃝ ⃝ ⃝ ⃝ 
Amphetamine (speed, gavana) ⃝ ⃝ ⃝ ⃝ 
Crystal methamphetamine (crystal, ice, 
tina, meth, taptap, crank) 
⃝ ⃝ ⃝ ⃝ 
Heroin (smack, mud, brown sugar) ⃝ ⃝ ⃝ ⃝ 
Mephedrone (meow meow, plant 
food, bubbles, kitty cat) 
⃝ ⃝ ⃝ ⃝ 
GHB/GBL (G, liquid ecstasy, soap) ⃝ ⃝ ⃝ ⃝ 
Cocaine or Crack cocaine (rock) ⃝ ⃝ ⃝ ⃝ 
Rohypnol (mchele, roofies, forget pill) ⃝ ⃝ ⃝ ⃝ 
Poppers (liquid gold) ⃝ ⃝ ⃝ ⃝ 
Benzene ⃝ ⃝ ⃝ ⃝ 
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K. MENTAL HEALTH 
The next set of questions are about how you have been feeling in the last two weeks. 
 
In the last two weeks how often have you been bothered by any of the following problems: 




K1. Little interest or pleasure in doing things 
 ⃝ ⃝ ⃝ ⃝ 
K2. Feeling down, depressed or hopeless 
 ⃝ ⃝ ⃝ ⃝ 
K3. Trouble falling or staying asleep, or sleeping too much 
 ⃝ ⃝ ⃝ ⃝ 
K4. Feeling tired or having little energy 
 ⃝ ⃝ ⃝ ⃝ 
K5. Poor appetite or overeating 
 ⃝ ⃝ ⃝ ⃝ 
K6. Feeling bad about yourself, or that you are a failure, or have let yourself or your family 
down 
 ⃝ ⃝ ⃝ ⃝ 
K7. Trouble concentrating on things, such as reading the newspaper or watching television 
 ⃝ ⃝ ⃝ ⃝ 
K8. Moving or speaking so slowly that other people could have noticed? Or the opposite – 
being so fidgety or restless that you have been moving around a lot more than usual 
 ⃝ ⃝ ⃝ ⃝ 
K9. Thoughts that you would be better off dead or of hurting yourself in some way 
 ⃝ ⃝ ⃝ ⃝ 
 
K10. If you checked off any of the problems above, how difficult have these problems made it for you to do your 
work, take care of things at home, or get along with other people? 
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L. POPULATION ESTIMATORS 
We now wish to ask whether or not you have used particular services recently. The answers to these questions will 
help us to estimate the number of MSM in the local area. No personal information will be passed on to or requested 
from any of these services to make this estimate. 
 
 [SHOW IF SITE = NAIROBI] 
L1. At [reference date], were you friends with the Facebook group ‘ISHTAR-MSM’? 
Yes 
No 
Do not know 
 
L2. Did you have an appointment at [Liverpool VCT or ISHTAR clinic] between [enter reference period] 
Yes  
No 
Do not know 
 
 [SHOW IF SITE = SOUTH AFRICA] 
L1. At [reference date], were you registered as a member of the Facebook group ‘Black Men Bold and the Beautiful’? 
Yes 
No 
Do not know 
 
L2. At [reference date], were you registered as a member of the Facebook group ‘Johannesburg Gays’? 
Yes 
No 
Do not know 
 
L3. At [reference date], were you registered as a member of the Facebook group ‘Soweto Gays’? 
  Yes 
  No 
  Do not know 
 
L4. At [reference date] were you following ‘We the Brave’ on Facebook?  
  Yes 
  No 
  Don’t know 
 
L5. At [reference date] were you following ‘Health 4 Men’ on Facebook? 
  Yes 
  No 
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M. HAPPINESS WITH SEX 
The last set of questions ask how happy you are with your sex life, and what might make it better. 
 
M1. How happy are you with your sex life right now? 
Very happy 
Quite happy 












Thank you very much for taking this survey. Your response is very important to us. 
 
If you feel you may have made any mistakes which you want to go back and correct, please mention this to the 
researcher who will help you. 
 
If the survey has made you think of questions about your health or about this research study, please ask the researcher.. 
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TRANSFORM Survey Instrument: Coupon Issue Module  
Date today:     [year/months/day]  
Site name: 
Study Staff name:  
Participant ID number:  
Coupon Number: 
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B1. How many other MSM do you know whom you have had a conversation with in the past month? By ‘know’, we mean 
someone who knows your name and you know theirs, and by 'had a conversation with', we mean either in person, on 
the phone, using SMS or online. 
[enter number] 
 





B3. How many of these [B2] men are 18 years of age or older? 
[enter number] 
 
Q9. How many of these [B3] men live in [Johannesburg’/Nairobi]? 
[enter number] 
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YOUR COUPON DISTRIBUTION (REFUSALS) 
We want to ask you about the people who did NOT accept a coupon from you. 
 
Q11  How many of the men you offered a coupon to, did not take one from you? 
  [enter number] 
 
Q12  [For each of [Q11]  
Thinking about the first man you offered a coupon too, that refused to take it, 
Why did that man not take a coupon from you? [tick all that apply] 
He said that he had already participated in the study  
He said that he had already received a coupon from someone else 
He said that he was not an MSM 
He said he was younger than 18 years old 
He said he was not from the same city as me 
He did not wish to participate in the study 
He said that there was not enough money for participating 
Other reason – say what 
None of the above 
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YOUR COUPON DISTRIBUTION (ACCEPTED) 
We now want to ask you about the people who did accept a coupon from you. 
Q13  How many men did you offer a coupon to who accepted it? 
[enter number 0-3] 
IF Q13>0  Concerning the first person you gave a coupon to: 
Q14i:  Thinking about the first man you offered a coupon too, that took it:  




Q14i:  Still thinking about the first man you offered a coupon too, that took it:  





Q14i:  Still thinking about the first man you offered a coupon too, that took it:  
What made you decide to give a coupon to this person? [Choose the most important reason] 
  He was the first eligible man I met  
  He is a close friend 
  He is my partner 
  He needed the money for participation 
  I thought he would benefit from the study 
  I put out an open request and he approached me 
Other (please say why ____________) 
 
LOOP Q14i FOR FURTHER COUPON RECIPIENTS 
[IF Q14>1] Concerning the second person you gave a coupon to: 
[IF Q14>2] Concerning the third person you gave a coupon to: 
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TRANSFORM Ithuluzi Lohlolo  
Ilanga Lokuhlolwa:     [unyaka/Inyanga/usuku] 
 
Igama lomhloli:                   _________________ 
 
Inombolo yepasi kambambiqhaza:    ____________________ 
 
Siyabonga ukuvuma ukwenza lolu hlolo. Manje sizokubuza imibuzo emayelana nawe. Sicela ukhumbule ukuthi 




Kunezinhlobo ezintathu zemibuzo eyinhloko, ejwayeleke kakhulu inamabhathini ayindilinga eceleni kwempendulo, 
futhi ikuvumela ukuthi ukhethe impendulo eyodwa. Uma usyichofozile impendulo, umbuzo uzonyamalala bese 
izoveza umbuzo olandelayo. Uma wenze iphutha, chofoza ibhathini eliwumcibisholo elikhomba esinxeleni (“EMUVA”), 
elingezansi kweskrini, esinxeleni. Awukuzame lokhu. 
 
Ngabe ubukeka kahle kangakanani? 
 Ngibukeka kahle 
 Ngibukeka kahle kakhulu 
 Ngibukeka kahle okungakholakali 
 
Eminye imibuzo inamabhathini amancane AYIZIKWELE eceleni kwezimpendulo futhi ungachofoza noma ezingaki 
izimpendulo ozithandayo. Uma usuyikhethile impendulo umbuzo ngeke inyamalale-uma usuqedile kudingakala 
ukuthi uchofoze ibhathini eliwumcibisholo okhomba kwesokudla (“OKULANDELAYO”) elingezansi kwesokudla. Uma 
wenze iphutha, chofoza ibhathini eliwumcibisholo elikhomba esinxeleni (“EMUVA”), elingezansi, esinxeleni. 
Awukuzame lokhu. 
 
Ngabe iziphi izinhlobo zemidlalo ozibuka kwiTV kulezi ezilandelayo? 
Isaziso lemibuzo ijwayele ukuba nesinezezelo esibhalwe ukuthi “OKUNYE”-uma uchofoza lokhu, kudingeka ukuthi 




 Okunye-sicela ukusho: (Kubhale) 
 
Eminye imibuzo embalwa ibuza ukuthi ugcine nini ukwenza into ethize, bese ikuvezela ikhalenda ukuze ukhethe usuku, 
inyanga Kanye nonyaka.Uma lokhu kwenzeka uyakwazi ukudlulisa izinyanga neminyaka usebenzisa imicibisholo 
ekhoma esandleni sesinxele noma kwesokudla kuyona ikhalenda. Uma usulukhethile usuku oluyimpendulo yakho, 
chofoza u “Set” ukukugcina okukhethile. Uma usuchofoze u “Set” umbuzo uzonyamalala bese kuvela olandelayo. 
Awukuzame lokhu. 
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Ugcine nini ukukhuluma noyedwa kumalunga omndeni wakho? 
 Kehetha usuku (usuku, inyanga, unyaka) 
 
 
AX. Coupon management 
Manje sesizoqala iseveyi kahle- ngicela uphendule yonke imibuzo ngeqiniso. Ngicela ukhumbule ukuthi asikho 
isidingo sokuthi uphendule imibuzo ongathandi ukuyiphendula futhi ungayimisa iseveyi nganoma ingasiphi isikhathi. 
Zonke izimpendulo zakho ziyimfihlo ngokuphelele. 
 
Uhlu lwemibuzo yokuqala ingokuthi, wazi kanjani ngalolucwaningo, nokuthi uyithathephi ikhuphoni.  
 
AX1. Umazi kanjani lomuntu okuphe ikhuphoni ukuthi ubambe iqhaza kukelithuluzi lohlolo? 
Umngani osendelene nami 
Umngani 
Umuntu engizwana naye 
Umuntu engingamazi 
Okunye  
Q1a, Uma u Q1 = Okunye buza, Ngabe umazi ngayiphi enye indlela? 
[Bhala] 
 
AX2. Bewulaphi ngesikhathiwuthola lelikhuphoni lokuzobamba iqhaza kulolucwaningo? 
Ekhaya noma eduzane nasekhaya 
Emsebenzini noma eduzane nasemsebenzini 
Siphumile emgwaqeni 
Endaweni zokuphuza nokuzijabulisa 
Ngaphandlekwalelihovisi 
Kwenye (Isho laphi ____________) 
 





AX4. Ngaphandle kwalomuntu okunikeze lelikhuphoni ofikenayo namhlanje, ngabe ukhona omunye umuntu 




AX5. Uma uvuma, lokhu kwenzeke kangaki? 
 [____] izikhathi 
 
A. Imibuzo eqondene nawe (1). 
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Uhlu lokuqala lwemibuzo lungawe, iminyaka yakho, lapho ohlala khona, Kanye nalapho owazalelwa khona. Leseveyi 
isiqalile-zonke izimpendulo zakho ziyimfihlo. Sicela uphendule imibuzo ngeqiniso. 




A2. Ingabe uhlala kuyiphi indawo? 
[SHOW IF SITENAME= NAIROBI] 
 Dagoretti  








Other (Ngicela ucacise) ____________ 
 SHOW IF SITENAME[SHOW IF SITENAME= SOUTH AFRICA] 










Other (please specify) ____________ 
 
 
A3. Ngabe wazalelwa e [Kenya / South Africa]? 
Cha 
Yebo [iya ku A5] 
 
A4. [uma u A3 kuwu Cha] Ingabe wazalelwa kuliphi izwe eAfrika? 
Yebo 
Cha  
A4a. [If A4 is yes] Iliphi izwe owazalelwa kulo eAfrika? 
  [Khetha kulohlu lwamazwe] 
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A6. [If A5 is no] Iliphi idolobha owazalelwa kulo? e? 
Idolobha/idolojana__________ 
 








A. Imibuzo eqondene nawe (2). 
A8. Ingabe wagcina kuliphi ibanga eskolweni owaliqeda? 
[SHOW IF SOUTH AFRICA]  
Angifundanga 
Amabanga okuqalisa 
Amabanga aphakeme  
Amabanga alekayo noma eTechnical Secondary  
Ikolishi noma inyuvesi noma isikhungo esiphakeme semfundo 
 
[SHOW IF KENYA]  
Angifundanga 
Amabanga okuqalisa 
Amabanga aphakeme  
Amabanga alekayo noma eTechnical Secondary  
Ikolishi noma inyuvesi noma isikhungo esiphakeme semfundo 
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A9. Iyiphi indlela echaza isimo sakho sokusebenza samanje? 
  Ngiqhashwe ngokwesikhathi esiphelele 
  Ngiqhashwe ngesikhathi esingaphelelanga 
  Ngiyazisebeza 
  Angisebenzi noma ngiphakathi kwemisebenzi 
  Okunye (__________) 
 
A11. Ngabe wenzemalini kulenyanga edlule? 
[SHOW IF KENYA] 
KSH [faka inani lemali] 
 
[SHOW IF SOUTH AFRICA]  
ZAR [faka inani lemali] 
 
A12. Kkufaka wena phakathi, bangaki abantu ababheke lomholo? 







A. Imibuzo eqondene nawe (3). 
 
 
A13. Ngabe eyiphi inkolo oyilandelayo? 
  Amakrestu 
  Islam 
  ubuHindu  
  okunye 
  Anginayo engiyilandelayo 
 





 Ngincama ukungasho 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-055783:e055783. 11 2021;BMJ Open, et al. Smith AD
 
TRANSFORM Zulu Survey Instrument 






A15. [SOUTH AFRICA ONLY] Ingabe ubuchaza kanjani ubuzocansi bakho? 
Ngiyindoda eya ecansini namanye amadoda. 
Ngiyindoda eya ecansini nabantu besifazane futhi namanye amadoda. 





A16. [SHOW IF KENYA]. Ubuchaza kanjani ubusocansi bakho ngesiSwahili? 
  Basha 
  Hanithi 
  Kuchu 
  Kuruzi 
  Msago 
  Msenge 
  Shoga 
  Okunye ( shano ukuthi kuphi_____________) 
 
 
A16. Yibuphi ubulili bakho bokuzalwa, (isibonelo, obuvela esitifiketini sokuzalwa)? 
Ngingowesilisa  
Ngingowesifazan 
Angifuni ukuphendula lomubuzo 
 




Angiyena owesilisa, owesifazane noma obulili obushintshiwe 
  
A18. Ngabe sithini isimo sakho sokushada? 
  Ngishadile/ umshado wenkantolo/ sihlalisene ngokusemthethweni 
  Ngisingili/ngihlukanisile/ ngiwumfelokazi[SKIP TO NEXT SECTION] 
 
A19. Ngabe ubulili buni uphathina wakho? 
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B. EZENHLALO: ABANGANI 
Manje sizokubuza imibuzo ngobungani bakho emadodeni aya ocansini namanye amadoda.  
 
B1. Ingabe mangaki amadoda aya ecansini namanye amadoda owaziyo oke waxoxisana nawo kulenyanga edlule? 
Ngokuthi ‘owaziyo’ sisho ukuthi umuntu enazana naye anamagama enixoxisene nabo, kungaba nibonene, noma 
ngocingo, nithumelane imilayezo ngocingo noma online? 
 [faka inani] 
B2. Ingabe mangaki kulamadoda [B5] azanayo? 
  bonke noma abaningi bayazana 
  Abaningi babo bayazana [around <ROUND[B5*.75]> of them] 
  Uhhafu wabo bayazana [around <ROUND[B5*.5]> of them] 
  Abanye, kodwa hhayi abaningi bayazana [around <ROUND[B5*.25]> of them]  
  Abancane kakhulu abazanayo  
 
B3 Ingabe mangaki lamadoda[B1] osuke wahlangana nawo? 
[faka inani] 
 
B4. . ingabe mangaki kulamadoda [B3] abangaphezu kweminyaka ewu 18 noma ngaphezulu? 
[faka inani] 
 
B5.Ingabe mangaki kulamadoda [B4] abahlala edolobheni elifanayo nawe? 
[faka inani] 
 





B7. Ingabe mangaki kulamadoda [B5] abangaphezu kweminyaka ewu 30? 
[faka inani] 
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Loluhlu lwemibuzo elandelayo ibuza ngezindlela ohlangana nazo namanye amadoda aya ocansini namanye amadoda. 















Umhlangano wangaphandle isb. epaki, 
emgaqweni noma ebhishi 
⃝ ⃝ ⃝ ⃝ 
EBar noma eklabhini ⃝ ⃝ ⃝ ⃝ 
Endlini yomngani noma eyami. ⃝ ⃝ ⃝ ⃝ 
ESauna, eBathhouse noma ephathini 
yocansi 
⃝ ⃝ ⃝ ⃝ 
Endaweni yomphakathi yamadoda alala 
namanye amadoda isb. iDrop in Centre 
noma isikhungo samadoda alala 
namanye amadoda  
⃝ ⃝ ⃝ ⃝ 
 
B9. Ugcine nini ukusebenzisa iwebhusayithi noma ama ephu ukwakha ubungani namanye ama MSM? 
Angikaze [jump to B12] 
Kulenyanga edlule 
Kulonyaka odlule 
Ngaphezu konyaka manje 
 
B10. Ngabe yimaphi kulamasevisi einthanethi osoke wawasebenzisa ukwakha ubungani nama MSM kulenyanga 
edlule [maka ibhokisi elinempendulo/izimpendulo zakho? 
2go ⃝ Facebook ⃝ Hornet ⃝   
Adam4Adam ⃝     Radar ⃝ 
  Gay Radar  ⃝ Instagram ⃝ Red Velvet ⃝ 
  Gay.com ⃝ iPlay ⃝ Scruff ⃝ 
Badoo ⃝ Gaydar ⃝   Sex Trader South Africa ⃝ 
      Skype ⃝ 
  Gayxchange ⃝ Mambaonline ⃝ Snapchat ⃝ 
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  Get Male ⃝ Manhunt ⃝   
  Grindr ⃝   Twitter  ⃝ 
    ManToManPlus ⃝ Twoo ⃝ 
Dating Buzz ⃝ Guy Spy ⃝ Men2Men ⃝ WeChat ⃝ 
      Whatsapp ⃝ 
    MISTER ⃝ Amanye ________  
  Hookups ⃝ Planet Romeo ⃝ 
  
 
B11. [Ngo Janwari 1 kulonyaka], ingabe ububhalisele ukusebenzisa lamasevisi elandelayo? 





B11.b. Planet Romeo 
  Yebo 
  Cha 
B11.c. Hornet 
  Yebo 
  Cha 
 
[SHOW IF COUNTRY=SOUTH AFRICA] 
 
B11.d. Mamba Online 
  Yebo 
  Cha 
 
[If yes to B11a] B11.e. NgoJanwari 1 kulonyaka, ubunamaprofayela amangaki kuGrindr? 
  [Faka inani] 
 
[If yes to B11b] B11.f. NgoJanwari 1 kulonyaka, ubunamaprofayela amangaki kuPlanet Romeo? 
  [Faka inani] 
 
[If yes to B11c] B11.f. NgoJanwari 1 kulonyaka, ubunamaprofayela amangaki kuHornet? 
  [Enter number] 
 
[If yes to B11d] B11.g. NgoJanwari 1 kulonyaka, ubunamaprofayela amangaki kuMamba Online? 
  [Enter number] 
 
 
B12. Uke wavakashela noma wamukela imininingwane kunhlangano yomphakathi noma iqembu lokwesekana 
lamaMSM? 
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Cha [JUMP TO NEXT SECTION] 
Angazi/anginasiqiniseko [JUMP TO NEXT SECTION] 
 
B13. Iyiphi kulezizinhlangano ezeseka abantu abathandana nabanye bobulili obufanayo oke wazivakashela 
kulonnyaka odlule? 
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C. UKWESEKWA KWENHLALO 
Loluhlu lwemibuzo elandelayo angokwesekwa ngokwenhlalo- noma ukwesekwa okuthola 
kuphathina/ophathina, abangani Kanye nomndeni. 

















C1. Kukhona umuntu obalulekile kimina ohlezi akhona mangimudinga 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C2. Kukhona umuntu obalulekile kimina ohlale akhona ezikhathini zobumnandi nobubi 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C3. Umndeni wami uyazama ukungisiza 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C4. Umndeni wami uyangeseka ngokomoya 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C5. Kukhona umuntu ongumduduzi empilweni yami 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C6. Abangani bami bangeseka ngaso sonke isikhathi 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C7. Abangani bami bahlale bengisekile ima izinto zingahambi kahle 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C8. Ngiyakhona ukukhuluma ngezinkinga zami nomndeni wami 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C9. Nginabangani esihlale sesekana nabo ngezikhathi ezimbi nezikhathi ezinhle 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C10. Nginomuntu empilweni yami okhathalela imizwa yami 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C11. Umndeni wami uyanginceda ekuthatheni izincumo ezibalulekile 
 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
C12. Ngiyakhona ukukhuluma nabangani bami ngezinkinga engihlangabezana nazo 
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 ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ ⃝ 
 
 
D.  EZENHLALO: UKWECWASANA NOBANDLULULO NGOKWEZOBULILI 
Loluhlu lwemibuzo elandelayo ingokwazisa abantu ngokuthi uyindoda eyaocansini namanye amadoda kanye 
nezinkinga ezibangwe ilokhu. 
Ngicela uqaphele mawuphendula lemibuzo. Eminye ikucela ukuthi ucabange ngezinyanga eziwu 12 ezedlule, 
ezinye zikucela ukuthi ucabange ngempilo yakho yonke. 
 





D2. Uke wezwa ngathi amalunga omndeni wakho ayakubandlulula noma bahleba ngawe ngoba uyindoda eya 




D3. Jikelele, kunzima kangakanani ukufihlela UMNDENI wakho ngokulala namanye amadoda? 
Ngizama kakhulu ukukufihla 
Ngiyazama nje ukukufihla 




D4.  Jikelele, uzama kangakanani ukufihlela abangani bakho ukuthi uya ocansini namanye amadoda? 
Ngizama kakhulu ukukufihla 
Ngiyazama nje ukukufihla 





D5. Uke wezwa engathi abangani bakho abathandi ukuzibandakanya nawe ngenxa yokuthi uya ocansini namanye 
amadoda? 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-055783:e055783. 11 2021;BMJ Open, et al. Smith AD
 
TRANSFORM Zulu Survey Instrument 






D6. Jikelele, uzama kangakanani ukugcina kuyimfihlo kubasebenzi basemitholampilo ukuthi uyindoda eya ocansini 
namanye amadoda? 
Ngizama kakhulu ukukufihla 
Ngiyazama nje ukukufihla 




D7. Kulezinyanga eziwu 12 ezedlule, uke wezwa usaba ukuya emtholampilo ngoba usaba ukuthi kukhona umuntu 




D8. Kulezinyanga eziwu 12 ezedlule, uke wezwa ungaphathekanga kahle emitholampilo ngoba kukhona umuntu 




D9. Kulezinyanga eziwu 12 ezedlule, uke wezwa uhletshwa noma uhlekwa abasebenzi basemtholampilo ngoba uya 














D12. Kulezinyanga eziwu 12 ezedlule, ukewacelwa ivalamlomo ngenxa yokuthi uya ocansini namanye amadoda 
  Yebo 
  Cha 
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D13. Kulezinyanga eziwu 12 ezedlule, kukhona umuntu okulimeze ngokomzimba (akuphushe, akuqindezele 
ekhoneni, akushaye ngempama, akushaye, akukhame, noma akulimaze ngokomzimba)? 
Yebo 
Cha [JUMP TO D20] 
 
D14. Ubani owenze lokhu? [Maka konke okufunayo] 
Umuntu engingamazi 
Ilunga lomndeni 






D15. Kulezinyanga eziwu 12 ezedlule, uke waphoqwa ukuthi uye ocansini ungafuni? (ngokuphoqa sichaza ukuthi 
Uphocwe ngokomzimba, ubanjwe ukuthi wenze ucansi, noma bakufake izinto, ungafuni). 
Yebo 
Cha [JUMP TO D24] 
 
D16. Ubani owenze lokhu? [Maka konke okufunayo] 
Umuntu engingamazi 
Ilunga lomndeni 






D17. Kulezinyanga eziwu12 ezedlule, uke wezwa usatshiswa ngokuthi uzobanjwa noma uzoboshwa yiphoyisa 
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E. UKUZIPHATHA NGEZOCANSI 
Singathanda mnje ukukubuza ngendlela yokuziphatha ngokwezocansi okusandakwenzeka. Ngocansi sichaza nama 
ikuphi okuphathelene nokuthinta izitho zangasese- sibala indlwabu (okwesitho sangaphambili, nokuzithokozisa 
ngomunwe esithweni sangasese); ucansi olwenziwa ngomlomo ( ukumunca/iblowjob,ukukhotha, ukukhotha isitho 
sangasese sangemuva); ucansi lwesithosangasese sangaphambili sowesifazane nome lwesitho sangemuva. 
 
E1. Kulezinyanga eziwu 3 ezedlule, ngabe ulwenzile ucansi nomuntu wesilisa? 
Yebo 
Cha 
E1a. [If E1 = yes ] be mangaki amadoda ahlukene oye nawo ocansini kulezizinyanga eziwu 3 ezedlule? 
[Faka inani] 
 




Akukho kuloku okubaliwe 
 
E3 [if E2= receptive or both] Kulezinyanga eziwu 3 ezedlule, ngabe uwasebenzise kangakanani amakhondomu 







E4. [if E2= receptive or both] Kulezinyanga eziwu 3 ezedlule, ngabe uwasebenzise kangakanani amakhondomu 








E5. Kulezinyanga eziwu 3 ezedlule ngabe wenze hloboluphi locansi lomlomo nabantu besilisa? 
Ngimuphe iblow job 
Ungiphe iblow job 
Ngmuphile futhi ngaphiwa iblowjob 
Akukho ngenhla 
 
E6. Kulezinyanga eziwu 12 ezedlule ngabe kukhona amadoda akukhokhele ukuthi wenze ucansi? 
Ngokukhokhelwa sisho imali, izipho noma ukusizwa ukuze wena wenze ucansi nabo. 
Yebo 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-055783:e055783. 11 2021;BMJ Open, et al. Smith AD
 
TRANSFORM Zulu Survey Instrument 






E7.. Kulezinyanga eziwu 12 ezedlule, ngabe uke wakhokhela indoda ukuthi iye ocansini nawe? 
Ngokukhokhelwa sisho imali, izipho noma uyisize ukuze yona yenze ucansi nawe.Yebo 
Cha 
E8. Kulezinyanga eziwu 12 ezedlule ingabe ukhona kophathina bakho oke wazama ukukulimaza? Ngaloku shisho 
ukukuphusha, akucindezele phansi, akushaye ngenqindi, akukhahlele, azame ukukuklinya, akuhlasele 




E9. Kulezinyanga eziwu 12 ezedlule, ngabe uphathina wakho wendoda usebenzise udlame noma wakuthusa 





E10. Kulezinyanga eziwu 3 ezedlule uke walwenza ucansi nomuntu wesifazanei? 
Yebo 
Cha 
E10a. Ngabe bangaki abantu besifazane owenze ucansi nabo kulezinyaka eziwu3?  
[Faka inani] 
 
E11. Kulezinyanga eziwu 3 ezedlule ingabe uluphi uhlobo locansi oke walwenza nabesifazane? 
Ucansi lwesitho sangasese sabesifazane sangaphambili 




E12. [if E11= vaginal or both] Kulezinyanga eziwu 3 ezedlule uyisebenzise kangakanani ikhondomu ngesikhathi 








E13 [if E11=anal or both] Kulezinyanga eziwu 3 ezedlule usebenzise kangakanani amakhondomu mawenza ucansi 
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E14.  Kulezinyanga eziwu 12 ezedlule ngabe ukhona owesifazane okukhokhele ukuthi uye naye ocansini? 




E15. Kulezinyanga eziwu 12 ezedlule, ngabe uke wakhokhela owesifazane ukuthi aye ocansini nawe? 






EX. UKUZIPHATHA KWEZOCANSI 
Manje sizokubuza imibuzo ngabantu ABANE oye nabo ocansini phambilini. Khetha igama lokuteketisa nima izicu 
zamagama abo kuze ukwazi ukubahlukanisa. Akumelanga kuba amagama abo angempela, kumele kube amagama nje 
ozokhona ukubahlukanisa ngawo. 
 
Khumbula masikhuluma ngocansi, sibala indlwabu (okwesitho sangaphambili, nokuzithokozisa ngomunwe esithweni 
sangasese); ucansi olwenziwa ngomlomo ( ukumunca/iblowjob,ukukhotha, ukukhotha isitho sangasese sangemuva); 
ucansi lwesithosangasese sangaphambili sowesifazane nome lwesitho sangemuva. 
 
Uphathina #1: 
Ubani ogcine ukuya naye ocansini? (Write in a nickname, first name or initials)  
[Faka amanishela] 
 
Uphathina # 2: 
Ngaphambi kuka (Partner #1) Ubani ogcine ukuya naye ocansini? ( Bhala igama lokudlala, Elokuqala noma 
amanishela) [Faka amanishela] 
 
Uphathina #3: 
Ngaphambi kuka (Partner #2) Ubani ogcine ukuya naye ocansini?? ( Bhala igama lokudlala, Elokuqala noma 
amanishela) [Faka amanishela] 
 
Uphathina #4: 
Ngaphambi kuka (Partner #3) Ubani ogcine ukuya naye ocansini? ( Bhala igama lokudlala, Elokuqala noma 
amanishela) [Faka amanishela] 
 
ROUTE 1: A CASUAL, ONE-OFF SEXUAL PARTNER 
[Partner #1] 
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Ngabe eliphi ilanga [eliduze kunanamuhla] ogcine ngalo ukwenza ucansi no[Partner #1]. Qagela uma 
ungasakhumbuli kahle 
[faka ilanga] 


















Kwi social network-isho ukuthi yiphi 
Okunye-isho ukuthi laphi      
Angikhumbuli 
 
Ngabe ucansi usulwenze kangaki no [partner #1] 
  Kanye kuphela 
  Kaningana 
 





Ngabe wamunika u[Partner #1] imali, izipho noma wamusiza ukuze enze ucansi nawe? 
  Cha 
  Yebo 
 
Ngabe u[Partner #1] wayekunika imali, izipho noma wakusiza ukuze wenze ucansi naye? 
  Cha 
  Yebo 
 
EX28 [i] [if EX3=male ] Ngabe nanenza luphi uhlobo locansi [Partner #1]? [Bheka okungenayo] 
   Ngangiyi Bhothomu 
   Ngangiyi Thophu 
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   Ngamupha iblow job 
   Ngaphiwa iblow job 
 
EX29A[i] [if EX3=male  & EX28 = receptive anal sex] Isikhathi ngangiyibhothomu no [Partner #1], Ngabe 
nasebenzisa ikhondomu noma cha? 
  Ngekhondomu 
  Ngaphandle kwekhondomu 
 
EX29B[i] [if EX3=male  & EX28 = insertive anal sex] Mawugcina ukuba yiThophu no [Partner #1], loku kwakunge 
noma ngaphandle kwekhondomu? 
  Ngekhondomu 
  Ngaphandle kwekhondomu 
 
 
EX30[i] [if EX3=female ] uhlobo luni locansi enalwenza no[Partner #1]? [Khetha okuyikona] 
  ucansi lwesitho sangasese sabesifazane sangaphambili  
  Ucansi lwesitho sangasese sangemuva 
  Ucansi lomlomo 
 
EX31A[i] [if EX3= female & EX28 = vaginal sex] ngesikhathi wenza ucansi lwesitho sangasese sabesifazane 
sangaphambili no [Partner #1], loku kwakunge noma ngaphandle kwekhondomu? 
 
  Ngekhondomu 
  Ngaphandle kwekhondomu 
 
EX31B[i] [if EX3= female & EX28 = anal sex] ngesikhathi nigcina ukwenza ucansi lwesitho sangasese sangemuva no 
[Partner #1], loku kwakunge noma ngaphandle kwekhondomu? 
  Ngekhondomu 
  Ngaphandle kwekhondomu 
 
EX33 [i] Uke u [Partner #1] wakutshela ngesimo sakhe seHIV? 
Yebo 
Cha [JUMP TO E35 [i]] 
Angazi 
 





SKIP TO E36[i] 
 
EX35[i] Wawukholwa ukuthi isimo sika [Partner #1] seHIV sithini ngesikhathi nenza ucansi naye? 
  Ngicabanga ukuthi [Partner #1] angaba nayi iHIV  
  Ngicabanga ukuthi u [Partner #1] akanayo iHIV 
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  Angazi 
 
ROUTE 2: A REGULAR SEXUAL PARTNER WHO THEY EXPECT TO HAVE SEX WITH AGAIN IN THE FUTURE 
 










Wayeneminyaka emingaki u[Partner #1] ngesikhathi nigcina ukwenza ucansi? Qagela uma unganasiqiniseko. 
[Faka iminyaka] 
 







Kwi social network-isho ukuthi yiphi 
Okunye-isho ukuthi laphi      
Angikhumbuli 
 
Ngabe ucansi usulwenze kangaki no [partner #1] 
  Kanye kuphela 
  Kaningana 
 




EX20A[i] [if EX19i=YES] Yikuphi kulokhu okulandelayo okuchaza ubudlelwane bakho no [Partner #1] bamanje? 
Sishadile 
Sesibe izithandani isikhathi eside 
Singabangani ababuye benze ucansi 
Sihlanganiswa ucansi 
 
EX21A[i] [if EX19i=YES] Uhlala naye u [Partner #1]? 
  Yebo 
  Cha 
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EX22A[i] [if EX19i=YES] Uyamthanda u [Partner #1]? 
  Yebo, kakhulu 
  Yebo, kancane 
  Cha 
 
EX24A[i] [if EX19i=YES] Ngabe ubheke ku <EX1[i]> ukuthola imali, umholo noma indawo yokuhlala? 
  Yebo, kakhulu 
  Yebo, kancane 
  Cha  
EX26[i]. Uke wamupha u [Partner #1] imali, izipho noma usizo, ubheke ukuthola ucansi? 
  Yebo 
  Cha 
EX27[i]. Uke u [Partner #1] akuphe imali, izipho noma usizo, ebebheke ukuthola ucansi? 
  Yebo 
  Cha 
 
EX28[i] [if EX3=male] Ngabe nanenza luphi uhlobo locansi no[Partner #1] ? [bheka okungenayo] 
   Ngangiyi Bhothomu 
   Ngangiyi Thophu 
   Ngamupha iblow job 
   Ngaphiwa iblow job 
 
EX29A[i] [if EX3=male & EX28 = receptive anal sex] Ngesikhathi uyibhothomu no [Partner #1], Ngabe nayisebenzisa 
ikhondomu noma cha? 
  Ngekhondomu 
  Ngaphandle kwekhondomu 
 
EX29B[i] [if EX3=male & EX28 = insertive anal sex] Mawugcina ukuba yoThophu no [Partner #1] loku kwakunge, 
noma ngaphandle kwekhondomu? 
  Ngekhondomu 
  Ngaphandle kwekhondomu 
 
 
EX30[i] [if EX3=female] uhlobo luni locansi enalwenza no<EX1[i]>? [Khetha okuyikhonaokuyikona] 
  Ucansi lwesitho sangasese sowesifazane sangaphambili  
  Ucansi lwesitho sangasese sangemuva 
  Ucansi lomlomo 
 
 
EX31A[i] [if EX3= female & EX28 = vaginal sex] 
Ngesikhathi nigcina ukwenza ucansi lwesitho sangasese sangaphambili sowesifazane no [Partner #1], ngabe lokhu 
kwakunge, noma ngaphandle kwekhondomu? 
Ngekhondomu 
  Ngaphandle kwekhondomu 
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EX31B[i] [if EX3= female & EX28 = anal sex]  
Ngesikhathi nigcina ukwenza ucansi lwesitho sangasese sangemuva no[Partner #1], ngabe lokhu kwakunge, noma 
ngaphandle kwekhondomu 
Ngekhondomu 




EX33[i] Uke u [Partner #1] wakutshela ngesimo sakhe seHIV? 









SKIP TO E36[i] 
 
EX35[i] Ukholwa ukuthi isimo sika [Partner #1] seHIV sithini? 
  Ngicabanga ukuthi angaba nayo iHIV  
  Ngicabanga ukuthi akanayo iHIV 
  Angazi 
  
EX36[i] Uke wena no [Partner #1] nakhaphana ukuyowenza loku okulandelayo [khetha okuyikho] 
Ukuyolulekwa nokuhlola iHIV 
Kuphoyinti lasemtholampilo wezocansi 
Kuphoyinti lomtholampilo wokulapha iHIV 
Umhlangano wezempilo wabantu besilisa abaya ocansini nabanye abantu besilisa 
Umcimbi ohlelewe inhlangano yabantu besilisa abaya ocansini nabanye besilisa 
Cha, akukho kulokhu okungenhla 
 
ROUTE 3: A FORMERLY REGULAR SEXUAL PARTNER WHO THEY DO NOT EXPECT TO HAVE SEX WITH AGAIN IN THE 
FUTURE 
 




U[Partner #1] ubulili buni?  
Owesilisa 
Owesifazane 
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Wayeneminyaka emingaki u[Partner #1] ngesikhathi nigcina ukwenza ucansi? Sicela uagele uma unganasiqiniseko. 
[Faka iminyaka] 
 







Kwi social network-isho ukuthi yiphi 
Okunye-isho ukuthi laphi      
Angikhumbuli 
 
Ngabe ucansi usulwenze kangaki no [partner #1] 
  Kanye kuphela 
  Kaningana 
 




EX20B[i] [if EX19i=YES] Yikuphi kulokhu okulandelayo okuchaza ubudlelwane owawunabo no [Partner #1] 
bamanje? 
Sasishadile 
Sesiyizithandani isikhathi eside/ophathina abaqavile 
Sasingabangani ababebuye benze ucansi 
Sasihlanganiswa ucansi 
 
EX21B[i] [if EX19i=NO & EX18i=YES] Nisenobudlelwano, wawuhlala naye u <EX1[i]>? 
  Yebo 
  Cha 
 
EX22B[i] [if EX19i=NO & EX18i=YES] Nisenobudlelwano, wawumthanda u <EX1[i]> 
  Yebo, kakhulu 
  Yebo, kancane 
  Cha 
 
EX24B[i] [if EX19i=NO] Ngabe wawubheke ku <EX1[i]> ukuthola imali, umholo noma indawo yokuhlala? 
  Yebo, kakhulu 
  Yebo, kancane 
  Cha  
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EX26[i]. Uke wamupha u [Partner #1] imali, izipho noma usizo, ubheke ukuthola ucansi? 
  Yebo 
  Cha 
EX27[i]. Uke u [Partner #1] wakupha imali, izipho noma usizo, ebebheke ukuthola ucansi? 
  Yebo 
  Cha 
 
EX28[i] [if EX3=male] Ngabe nanenza luphi uhlobo locansi no[Partner #1] ? [bheka okungenayo] 
   Ngangiyi Bhothomu 
   Ngangiyi Thophu 
   Ngamupha iblow job 
   Ngaphiwa iblow job 
 
EX29A[i] [if EX3=male & EX28 = receptive anal sex] Ngesikhathi uyibhothomu no [Partner #1], Ngabe nayisebenzisa 
ikhondomu noma cha? 
  Ngekhondomu 
  Ngaphandle kwekhondomu 
 
EX29B[i] [if EX3=male & EX28 = insertive anal sex] Mawugcina ukuba yoThophu no [Partner #1] loku kwakunge, 
noma ngaphandle kwekhondomu? 
  Ngekhondomu 
  Ngaphandle kwekhondomu 
 
 
EX30[i] [if EX3=female] uhlobo luni locansi enalwenza no[Partner #1]? [Khetha okuyikhonaokuyikona] 
  Ucansi lwesitho sangasese sowesifazane sangaphambili  
  Ucansi lwesitho sangasese sangemuva 
  Ucansi lomlomo 
 
 
EX31A[i] [if EX3= female & EX28 = vaginal sex] 
Ngesikhathi nigcina ukwenza ucansi lwesitho sangasese sangaphambili sowesifazane no [Partner #1], ngabe lokhu 
kwakunge, noma ngaphandle kwekhondomu? 
Ngekhondomu 
    Ngaphandle kwekhondomu 
 
 
EX31B[i] [if EX3= female & EX28 = anal sex]  
Ngesikhathi nigcina ukwenza ucansi lwesitho sangasese sangemuva no[Partner #1], ngabe lokhu kwakunge, noma 
ngaphandle kwekhondomu 
Ngekhondomu 
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EX33[i] Uke u [Partner #1] wakutshela ngesimo sakhe seHIV? 









SKIP TO E36[i] 
 
EX35[i] Wawukholwa ukuthi isimo sika [Partner #1] seHIV sithini ngesikhathi nigcina ukwenza ucansi? 
  Ngicabanga ukuthi angaba nayo iHIV  
  Ngicabanga ukuthi akanayo iHIV 
  Angazi 
  
EX36[i] Uke wena no [Partner #1] nakhaphana ukuyowenza loku okulandelayo [khetha okuyikho] 
Ukuyolulekwa nokuhlola iHIV 
Kuphoyinti lasemtholampilo wezocansi 
Kuphoyinti lomtholampilo wokulapha iHIV 
Umhlangano wezempilo wabantu besilisa abaya ocansini nabanye abantu besilisa 
Umcimbi ohlelwe inhlangano yabantu besilisa abaya ocansini nabanye besilisa 
Cha, akukho kulokhu okungenhla 
 
Ukuqedela loluhlu sesizokubuza imibuzo emibalwa, emayelana nokwazana kwalabophathina oqeda kubabala 
 
 
EX37 [IF >1 MALE]  Ngokwazi kwakho, bakhona kulabantu besilisa abenza ucansi ndawonye, baphinde balwenze 
futhi nawe? 
Yebo 
Cha [SKIP TO NEXT SECTION] 
Angazi [SKIP TO NEXT SECTION] 
 
EX38 [IF >1 MALE REPORTED] Sicela uveze ukuthi ibaphi abenza ucansi ndawonye 
<EX1> & <EX2> [IF BOTH MALE] 
<EX1> & <EX3> [IF BOTH MALE] 
<EX1> & <EX4> [IF BOTH MALE] 
<EX2> & <EX3> [IF BOTH MALE] 
<EX2> & <EX4> [IF BOTH MALE] 
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NOKUZAZI KWAKHO NGE HIV NOKUPHEPHA KWEZOCANSI. 
Loluhlu lwemibuzo elandelayo ingokwaziyo ngeHIV Kanye nokuthi ukuthola kulula kangakanani ukunakekela 
ezempilo zakho zocansi. 
F1. Yonke lemibhalombiko IYIQINISO. UBUKWAZI YINI LOKHU OKULANDELAYO? 
 











F1c. Kuyenzeka ukuthi uthole iHIV noma uyitop manenza ucansi lwesitho sangansense sangemuva sabantu besilisa. 
















F2a. ‘Ucansi engilwenzayo luhlale luphephile ngendlela engifuna ngayo mina’ 
 ⃝ ⃝ ⃝ ⃝ ⃝ 
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F2b. ‘Ngingasenza isiciniseko sokuthi ngisebenzisa amacondom uma kumele asetshenziswe’ 
 ⃝ ⃝ ⃝ ⃝ ⃝ 
F2c. ‘ngesinye isikhathi ngiba nobunzima bokuthola ama condom mangiwadinga’ 
 ⃝ ⃝ ⃝ ⃝ ⃝ 
F2d. ‘ngesinye isikhathi ngiba nenkinga nama condom angangeni kahle’ 
 ⃝ ⃝ ⃝ ⃝ ⃝ 
F2e. ‘ngesinye isikhathi ngiba nenkinga ukuthola ilubhu yamanzi mangiyidinga’ 
 ⃝ ⃝ ⃝ ⃝ ⃝ 
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G. EZEMPILO ZOCANSI NE HIV 
Loluhlu lwemibuzo elandelayo ingokuhlolela iHIV 
G1. Ukholwa ukuthi isimo sakho seHIV simephi namuhla? 
Anginayo iHIV (ngicabanga ukuthi anginayo iHIV) 
Nginayo iHIV (ngicabanga ukuthi nginayo iHIV) 
Angicinisekanga 
 
G2. Uke wahlola igazi uhlola iHIV? 
Yebo 
Cha [jump to section G PART III] 
 
 
G3. Iyiphi inyanga nonyaka owagcina ukuhlolela iHIV? 
[faka usuku MM/YYYY] 
 
G4. Ukugcina kwakho ukuhlola iHIV, ugcinephi? 
Esibhedlela noma eklinikhi yomphakathi 
Esibhedlela noma eklinikhi ezimele 
Endaweni yokuhlolela iHIV yomphakathi wonke 
Endaweni yomphakathi lapho khona kuhlola khona abantu besilisa abathandana nabanye abantu besilisa.Endaweni 
lapho engihlangana nabangani (ebar noma eKlubhini)  
Ngizihlole mina ekhaya 
. 
Okunye [ Ngicela uchaze]G5. Ukugcina kwakho ukuhlola iHIV, waneliseka kangakanani ngendlela ekumele kufihleke 
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G8. Yayithini imiphumela yokuhlola yamaduzane yeHIV?  




Section G Part i: About being HIV positive  
Loluhlu lwemibuzo elandelayo imayelana nokuzithola uneHIV 
G10. Kwakungayiphi inyanga noma unyaka uma uthola ukuthi unayo I IHV? 
[faka ususku MM/YY] 
 
G11. Kusukela ngalesikhathi uthola ukuthi unayo iHIV, usuke wadluliselwa yini emtholampilo ukuyohlolisisa ngayo 
iHIV noma ngesimo sakho sempilo? Ngokuthi ‘Emtholampilo’ sisho icliniki lapho ubona khona udokotela noma 





G12. Kusukela ngesikhathi waqala ukuthola ukuthi une HIV, uke wavakashela umtholampilo nge HIV noma izifo 
ezihambelanayo?? 
Yebo [JUMP TO G14] 
Cha  
 
G13 Kungani ungavakashelanga umtholampilo emva kokuthi uthunyelwe khona?? (khetha okungenayo) 
Indlela yokuziphatha yabantu abasebenza emtholampilo kuma MSM 
Indlela yokuziphatha yabasebenzi basemtholampilo kubantu abaphila neHIV 
ukwesaba ukubonwa mangiya emtholampilo 
Indlela ende ukuya emtholampilo 
Ukudula komtholampilo/ukuhlola 
Ukudula ukuya emtholampilo 
Ukudula komuthi 
Ukusaba ukugula okuza nokuthatha umuthi 
Ukusaba ukuthi umuthi uzobonwa abantu 
Angikholwanga ukuthi umuthi uyasebenza 
Angikholwanga ukuthi ngiyawudinga umuthi 




G14. Kusukela ngelanga owazi ngalo ukuthi unayo iHIV, kwaba duzane kangakanani ukubonana nomuntu osebenza 
emtholampilo ngokunakekela iHIV? 
Ngalelo langa engazingalo ngesimo sami 
Emavikini amabili emuva kokwazi ngesimo sami 
Emaviki ayi2 kuya ku4 emuva kokwazi ngesimo sami 
Izinyanga eziwu1 kuya ku3 emuva kokwazi ngesimo sami 
Ezinyangeni eziwu 3 kuya ku 12 emuva kokwazi ngesimo sami 
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Ngaphezulu konyaka ngazi ngesimo sami 
ADDED Angikaze ngibonane nomuntu osebenza emtholampilo ngokunakekela iHIV 
 
G15. Uye kuphi mawuqala ukuvakashela umtholampilo ngalenhloso? 
Esbhedlela somphakathi noma iKliniki 
Esbhedlela esizimele noma ikliniki 
Ekliniki yabesilisa abaya ocansini nabanye besilisa 
 
UKUNAKEKELA IHIV OKUQHUBEKAYO 
G16. Ugcine nini ukubonana nowezempilo osemthethweni mayelana nokunakekelwa kwe HIV?  
Kulezinyanga eziwu 6 zokugcina 
Phakathi kwezinyanga eziwu 6 kuya kweziwu 12 
Phakathi kweminyaka eyi1 kua ku 2 
Eminyakeni endlula eyiwu 2 eyedlule 
 
G17. Uye kuphi ngesikhathi ugcina emtholampilo ngalenhloso? 
Esbhedlela somphakathi noma iKliniki 
Esbhedlela esizimele noma ikliniki 
Ekliniki yabesilisa abaya ocansini nabanye besilisa 
 
G18. Ngesikhathi ugcina ukuya emtholampilo ukuyohlola ngokunakekelwa kwe HIV, waneliseka ngobumfihlo 
bamasevisi abo? 




Angikhumbuli/ Angicabangi ngakho 
 
 
G20. Ngesikhathi ugcina ukuvakashela umtholampilo ngokunakekela iHIV, waneliseka yini ngenhlonipho 
abasebenzi abakubonisa yona? 











G22a. [If G22 = yes] Ugcine nini ukwenza lolo hlolo lwe CD4? 
Kulezinyanga eziyisithupha ezedlule 
Phakathi kwenyanga eziyisithupha kuya ezinyangeni eziyishumi nambili ezedlule 
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Phakathi konyaka noma iminyaka emibili eyedlule 
Ngaphezu kweminyaka emibili endlule 
 
G23. [If G22 = yes]Sasithini isibalo sakho se CD4 ngesikhathi uyohlola? 
Ngaphezu kuka 500 
Phakathi kuka 350 kuya ku 500 
Ngaphansi kuka 350 
Bangitshela kodwa angisakhumbuli 









G24a. [If G24 = yes] Ugcine nini ukuthola imiphumela yakho ye viral load? 
Angizange  
Ezinyangeni eziwu 6 
Phakathi kwezinyanga eziwu6 kuya ku 12 
Phakathi konyaka neminyaka ewu 2 
Sekudlule iminyaka ewu 2 
 
G25. [If G24 = yes] Ibithini imiphumela yokuhlolwa kwe viral load mawugcina ukuhlola? 
Ayibonakalanga 
Yabonakala 
Bangithsela kodwa angikhumbuli 
Bangitshela kodwa angizwisisanga 
Abangitshelanga imiphumela 
 
UKKWELASHWA KWE HIV (ART) 
Loluhlu lwemibuzo elandelayo ingokuthatha imithi edambisa iHIV (ART, HAART). 
G26. Ingabe sewuqalile yini ukuthatha ama antiretroviral (ngesinye isikhathi aziwa ngokuthi yi ART [antiretroviral 
treatment] noma HAART [highly-active antiretroviral therapy] eHIV? 
Yebo 
Cha [JUMP TO G28] 
 
G27. Uthe uzwa ngesimo sakho seHIV mhlaka <G8 MM YY>. Waqala duzane kanganani ukuthatha amaART akho 
emuva kwalokho?  
Ngalelo langa engazingalo ngesimo sami 
Emavikini amabili emuva kokwazi ngesimo sami 
Emavikini awi2 kuya ku4 emuva kokwazi ngesimo sami 
Izinyanga eziwu1 kuya ku3 emuva kokwazi ngesimo sami 
Ezinyangeni eziwu 3 kuya ku 12 emuva kokwazi ngesimo sami 
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Ngaphezulu konyaka ngazi ngesimo sami 
[JUMP TO SECTION G PART IV] 
 
G28. Ingabe okusizayo ngendaba zempilo usekululekile ukuthi uqale uthathe ama antiretroviral treatment (ART)?  
Yebo 
Cha [JUMP TO SECTION G PART IV] 
 
G29. Ingabe yini eyakwenza ukuthi ungaqali ukuthatha umshanguzo wama antiretroviral treatment (ART)?  
[Khetha konke okungenayo] 
Indlela yokuziphatha yabantu abasebenza emtholampilo kuma MSM 
Indlela yokuziphatha yabasebenzi basemtholampilo kubantu abaphila neHIV 
Ukwesaba ukubonwa mangiya emtholampilo 
Indlela ende ukuya emtholampilo 
Ukudula komtholampilo/ukuhlola 
Ukudula ukuya emtholampilo 
Ukudula komuthi 
Ukusaba ukugula okuza nokuthatha umuthi 
Ukusaba ukuthi umuthi uzobonwa abantu 
Angikholwanga ukuthi umuthi uyasebenza 
Angikholwanga ukuthi ngiyawudinga umuthi 
Ezinye izizathu [sicela ucacise_______________] 
 








[If G30 = no]Uyeke nini ukuthatha ama antiretroviral treatment (ART)? 
Kulezinyanga eziyisithupha ezedlule 
Phakathi kwenyanga eziyisithupha kuya ezinyangeni eziyishumi nambili ezedlule 
Phakathi konyaka noma iminyaka emibili eyedlule 
Ngaphezu kweminyaka emibili endlule 
 
[If G30 = no] 
G32. Ingabe yini eyakwenza ukuthi uyekele ukuthatha iantiretroviral treatment? [Khetha okungenayo] 
Indlela yokuziphatha yabantu abasebenza emtholampilo ebhekiswe kuma MSM 
Indlela yokuziphatha yabasebenzi basemtholampilo kubantu abaphila neHIV 
Ukwesaba ukubonwa mangiya emtholampilo 
Indlela ende ukuya emtholampilo 
Ukudula komtholampilo/ukuhlola 
Ukudula ukuya emtholampilo 
Ukudula komuthi 
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Ukusaba ukugula okuza nokuthatha umuthi 
Ukusaba ukuthi umuthi uzobonwa abantu 
Angikholwanga ukuthi umuthi uyasebenza 
Angikholwanga ukuthi ngiyawudinga umuthi 
Ezinye izizathu [sicela ucacise_______________] 
 
 
[If G30 = yes] G31. Iningi leziguli likuthola kunzima ukuthatha imithi yeHIV belandela indlela abatshelwe ngayo. 
Ngabe mangaki amadozi yemithi yakho yeHIV ongawathathanga kulezizinsuku eziwu7 ezedlule? 
   
  [Fa]ka inani lama dozi 
 
 
ISIGABA G INXENYE II. NGOKUNGABI NE HIV 
Loluhlu lwemibuzo elandelayo imayelana nokungabi nayo iHIV 
 
G33. Kullezinyanga eziwu12 ezedlule, uye kangakhi ukuyohlola iHIV? 
        [faka inani] 
  
G34. Mangabe uyanquma ukuhlolela iHIV futhi, ungafuna ukuhlolelaphi?  
Esbhedlela somphakathi noma iKliniki 
Esbhedlela esizimele noma ikliniki 
Isevisi yomphakathi yokuhlola iHIV 
  Isevisi yomphakathi yokuhlola iHIV yabesilisa abaya ocansini nabesilisa 
  Endaweni lapho ngihlangana nabangani (e.g. bars or clubs) 
  Ekhaya 
 
G35. Uma unganquma ukuhlola iHIV futhi, ubani ongathanda ukuthi akwenze lohlolo? 
Udokotela noma umsebenzi wezempilo 
Unesi 
Ikhansela 
Osebenzela umphakathi wama MSM 
Imina [i.e. ukuzihlola] 
 
[JUMP TO SECTION G PART IV] 
 
ISIGABA G INXENYE III: NGOKUNGAYIHLOLELI NHLOBO IHIV 
 
Loluhlu lwemibuzo lungokungayihloleli nhlobo iHIV 
 
G36.  Kungani ungakahloli isimo sakho se HIV?? 
  [enter text] 
Ngikhathazekile ukuthi angeke bangiphathe ngenhlonipho emtholampilo 
Akubalulekike kimi ukuthi ngazi  
Ngoba ngicabanga ukuthi isimo sami siyafana neskaphathini wami 
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Angazi ukuthi ngiyosihlola kuphi 
Ngiyasaba ngoba ngicabanga ukuthi nginayo iHIV 
Ngiysaba ukuthi abantu ngeke basangiphatha kahle uma ngiyohlola 
Ngisaba ukuthi uma ngineHIV abantu ngeke basangiphatha ngendlela ejwayelekile 
Kunganibangela izinkinga ebudlelwaneni bami 
Anginaso isizathu esingangenza ngibe neHIV 
Esinye isizathu (isho________________) 
 







G38. Uma ungancuma ukuthi uyozihlola ngelinye ilanga, ungathanda ukuhlolaphi?  
Esbhedlela somphakathi noma iKliniki 
Esbhedlela esizimele noma ikliniki 
Ekliniki yabesilisa abaya ocansini nabanye besilisa 
  Isevisi yomphakathi yokuhlola iHIV yabesilisa abaya ocansini nabesilisa 
  Endaweni lapho ngihlangana nabangani (e.g. bars or clubs) 
  Ekhaya 
 
 
G39. Uma ungancuma ukuthi uyohlola ngelinye ilanga, ungathanda ukuhlolwa ngubani? 
Udokotela noma umsebenzi wezempilo 
Unesi 
Ikhansela 
Osebenzela umphakathi wama MSM 
Mima [i.e. ukuzihlola] 
 
 
SECTION G PART IV: EZINYE IZIFO EZITHATHELELANA NGOCANSI 
 
G40. Kulezinyanga eziwu 12 ezedlule, uke waphuma ubovu esithweni sakho somzimba sangansense sangaphambili 
noma kube buhlungu uma uchama? 
Yebo 
Cha [JUMP to G35] 
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G42. Kulezinyanga eziyishumi nambili ezedlule, ingabe uke waphuma ubovu noma igazi esithweni sakho somzimba 
sangansense sangemuva noma uzwe ubuhlungu obungabekezeleleki uma wenza ucansi  esithweni sakho 
somzimba sangansense sangemuva? 
Yebo 
Cha [JUMP to G44] 
 




G44. Kulezinyanga eziyishumi nambili ezedlule, uke wabona izilonda esithweni sakho somzimba sangasese 
sangaphambili nesesithweni sakho somzimba sangasese sangemuva? 
Yebo 
cha 
 [IF A16 = A17 JUMP TO NEXT SECTION] 
 
SECTION G PART V: TRANSGENDER SEXUAL HEALTH ACCESS 







G46. Ingabe njengamanje uyawasebenzisa amahomoni noma amahomoni avimba ukwelapha? 
  Yebo 
  Cha [SKIP TO G48] 
 
G47. Ingabe ukutholaphi lokwelapha? 
  Isibhedlela somphakathi 
  Isibhedlela sangansese 
  Ngawathenga ekhemisi 
  Ngawathenga kuinthanethi 
Ngawathola kubangani 
[SKIP TO G49] 
 








G49. Usuke wahlinzwa ukuze ushintshe ubulili? 
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  Yebo 
  Cha [SKIP TO G51] 
 
G50. Where were you able to access these services? 
  Esbhedlela somphakathi khona kulelizwe 
  Isibhedlela esizimele kulelizwe 
  Esbhedlela kwelinye izwe 
[JUMP TO NEXT SECTION] 
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H. Post Exposure Prophylaxis (PEP) and Pre Exposure Prophylaxis (PrEP)  
Loluhlu lwemibuzo elandelayo inge Post Exposure Prophylaxis-ebuye yaziwe nge PEP. 
 
H1. Lesitatimenti esilandelayo siyiqiniso. Ingabe ubusukwazi lokho? 
 
I Post Prophylaxis (PEP) amaphilisi athathwa inyanga yonke avikela ukuthi umuntu angatheleleki ngeHIV uma 
bevulelekile kuyona, (kufana nokuya ecansini ungafakanga icondom). iPEP ifuna ukuthathwa emuva kokuvuleleka  
engcupheni ye HIV. 
Bengivele ngikwazi lokhu 
Bengingaso isiciniseko salokhu 
Bengivele ngingakwazi lokhu 
Angikuzwisisi lokhu 
 









H4. [If yes to H3] IPEP uyithathe amalanga ayingakhi? (Uma uyithathe kaningi kunakodwa, cabanga ngeseikhathi 
owagcina ngayo ukuyithatha) 
[faka inani]  
 





H. Pre Exposure Prophylaxis (PrEP)  
The next set of questions is about Pre Exposure Prophylaxis - which is also known as PrEP. 
 
H6. Lesitatamende esilandelayo siyiqiniso . Ubusuwazi ngaloku? 
. iPre exposure prophylaxis (PrEP) ifaka phakathi umuntu onganayo iHIV othatha ipilisi ngesikhathi esihambayo 
ukuzivikela ekutholeni iHIV. Abantu abaningi abasebenzisa iPrEP onke amalanga. IPrEP idinga ukuthi uyithathe 
ngaphambi kokuya ocansini ukuze ikwazi ukusebenza.  
Besengikwazi lokhu 
Benginganaso isiciniseko salokhu 
Bengingakakwazi lokhu 
Angikuzwisisi lokhu 
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PrEP ihlukile kune PEP, iPEP ithathwa emuva kokuvuleleka iPrEP yona ithathwa ngaphambi kokuvuleleka. 
 
H7. Uke wazama ukuthola iPrEP? 
Yebo 
Cha [JUMP TO H10] 
Angazi [JUMP TO H10] 
 
H8. Usake wanikezwa iPrEP? 
  Yebo 
  Cha 
  Angazi 
 
H8. Usake wayithatha iPrEP? 
Yebo, futhi ngisayisebenzisa 
Yebo, ngiyekile ukuyisebenzisa 
Cha [JUMP TO H10] 
Angazi [JUMP TO H10] 
 
H9. Wayitholaphi iPrEP?  
Udokotela esibhedlela somphakathi noma ekliniki 
Udokotela esibhedlela esizimele noma ekliniki 
Enhlanganweni yomphakathi  
Kuwebhusayithi ezimisele (shano ukuthi yiphi) 
Kwenye indawo (shano ukuthi kuphi) 
 
[JUMP TO NEXT SECTION] 
 








H11. Uma iPrEP ingenziwa ukuthi itholakale, ungathanda ukuyitholaphi?  
Udokotela esibhedlela somphakathi noma ekliniki 
Udokotela esibhedlela esizimele noma ekliniki 
Enhlanganweni yomphakathi  
Ekhemisi 
Kuwebhusayithi ezimisele (shano ukuthi yiphi) 
Kwenye indawo (shano ukuthi kuphi) 
 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-055783:e055783. 11 2021;BMJ Open, et al. Smith AD
 
TRANSFORM Zulu Survey Instrument 




BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-055783:e055783. 11 2021;BMJ Open, et al. Smith AD
 
TRANSFORM Zulu Survey Instrument 
SA IsiZulu Version 2.0; 09 Mar 17 
 
40 
ISAHLUKO I. UKUSETSHENZISWA KOTSHWALA 
I1. Uziphuza kangakanani izinto ezinotshwana 
Angikaze 
Njalo ngenyanga 
Kabili ukuya kane enyangeni 
Kabili ukuya kathathu ngesonto 
Kane noma kaningi ngesonto 
I2. Uma uphuza utshwala, uphuza iziphuzo ezingakhi? 
1 noma 2 
3 noma 4 
5 noma 6 
7 kuya ku 9 
10 noma adlulayo 





Ngelanga noma cishe onke amalanga 





Ngelanga noma cishe onke amalanga 
 
I5. Kukangaki kulonyaka odlule lapho uzithole khona uhluleka ukuziphatha ngendlela ejwayelekile ngoba 
ubuphuzile? 
Angikwenzi 
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Ngelanga noma cishe onke amalanga 
 






Ngelanga noma cishe onke amalanga 
 





Ngelanga noma cishe onke amalanga 
 






Ngelanga noma cishe onke amalanga 
 
I9. Uke noma omunye umuntu walimala ngoba wena ubuphuzile? 
Cha  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2021-055783:e055783. 11 2021;BMJ Open, et al. Smith AD
 
TRANSFORM Zulu Survey Instrument 
SA IsiZulu Version 2.0; 09 Mar 17 
 
42 
Yebo, kodwa hhayi kulonyaka odlule 
Yebo, kulonyaka odlule 
I10. Ngabe isihlobo, umngani, udokotela noma isisebenzi sezempilo bake babonisa ukukhathazeka ngokuphuza 
kwakho? 
Cha  
Yebo, kodwa hhayi kulonyaka odlule 
Yebo, kulonyaka odlule 
 
 
ISAHLUKO J. UKUSEBENZISA KWEZIDAKAMIZWA 
Loluhlu lwemibuzo elandelayo ingokusebenzisa kwakho ugwayi noma ezinye izidakamizwa. 
J1. Ngicela ucacise uma usake wakusebenzisa lokhu okulandelayo: 










Tobacco ⃝ ⃝ ⃝ ⃝ 
Cannabis (grass, weed, herb, ndom, 
bhang, ganja, dagga, zol, insangu) 
⃝ ⃝ ⃝ ⃝ 
Khat (miraa, veve, mogoka) ⃝ ⃝ ⃝ ⃝ 
Ecstasy (E, umgwinyo, happy pill, disco 
biscuit, Adam) 
⃝ ⃝ ⃝ ⃝ 
Amphetamine (speed, gavana) ⃝ ⃝ ⃝ ⃝ 
Crystal methamphetamine (crystal, 
ice, tina, meth, taptap, crank) 
⃝ ⃝ ⃝ ⃝ 
Heroin (smack, mud, brown sugar) ⃝ ⃝ ⃝ ⃝ 
Mephedrone (meow meow, plant 
food, bubbles, kitty cat) 
⃝ ⃝ ⃝ ⃝ 
GHB/GBL (G, liquid ecstasy, soap) ⃝ ⃝ ⃝ ⃝ 
Cocaine or Crack cocaine (rock) ⃝ ⃝ ⃝ ⃝ 
Rohypnol (mchele, roofies, forget pill) ⃝ ⃝ ⃝ ⃝ 
Poppers (liquid gold) ⃝ ⃝ ⃝ ⃝ 
Benzene ⃝ ⃝ ⃝ ⃝ 
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K. UKUPHILA KWENGCONDO 










K1. ngimomdlandla omncane ekwenzeni izinto 
 ⃝ ⃝ ⃝ ⃝ 
K2. ngizizwa ngiphansi ngikhathazekile futhi nginganathemba 
 ⃝ ⃝ ⃝ ⃝ 
K3. Inkinga yokulala noma ukuhlala ngilele, noma ukulala ngokweqile 
 ⃝ ⃝ ⃝ ⃝ 
K4. ukuzizwa ngikhathele noma ngimanandla amancane 
 ⃝ ⃝ ⃝ ⃝ 
K5. Ukungadleki noma ukudla kakhulu 
 ⃝ ⃝ ⃝ ⃝ 
K6. ngizizwa kabi ngami, noma ngizizwe njengesehluleki, noma ngizicekele phansi ngacekela 
nomndeni wami phansi 
 ⃝ ⃝ ⃝ ⃝ 
K7. Inkinga yokugxilisa ingqondo ezintweni ezifana nokufunda iphephandaba noma 
ukubheka umabonakude 
 ⃝ ⃝ ⃝ ⃝ 
K8. Ukuhamba noma ukukhuluma kancane ukuthi abantu banganaki nokunaka? Noma 
okuhlukile, okuba ukungahlaliseki nokungaphumuli okufaka nokuhambahamba ukudlula 
injwayelo. 
 ⃝ ⃝ ⃝ ⃝ 
K9. Imicabango yokuthi kungabangcono mawungafa noma yokuzilimaza ngendlela thize. 
 ⃝ ⃝ ⃝ ⃝ 
 
K10. Uma kukhona inking oyikhethile, ubunzima obunganani lezinkinga ezibenzile ekwenzeni umsebenzi wakho, 
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L. UKUQAGELA INANI LABANTU  
Manje sifisa ukukubuza ukuthi uke wasebenzisa amasevisi akhethekile kulamalanga. Izimpendulo zalemibuzo 
zisosinceda ukuthi sithole inani labantu abesilisa abaya ocansini nabanye abantu besilisa. Ayikho iminingwane 
engawe ezodluliswa noma ezocelwa kulamasevisi ukucagela lenani. 
[SHOW IF SITE = NAIROBI] 
 [SHOW IF SITE = NAIROBI] 








 [SHOW IF SITE = SOUTH AFRICA] 




  Angazi 
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M. UKUJABULA KWEZOCANSI 
 






M2. Yini into eyodwa engakusiza ukuthi impilo yakho yezocansi ibe ngcono? 
[Bhala] 
M3. Iyiphi indoda ebukeka kahle kunawo wonke emhlabeni? 
[Bhala] 
 
Siyabonga kakhulu ngokubamba kwakho iqhaza kulolucwaningo. Uma uzwa ngathi knona amaphutha owenzile ufisa 
ukubuyela emuva uyowalungisa, ngicela uwasho kumcwaningi ozobe ekusiza. Uma loqwaningo lukwenza ucabange 
ngemibuzo engempilo yakho nangalocwaningo, sicela ubuze umcwaningi. 
 
Luyaphela lapho uhla lemibuzo. 
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TRANSFORM Survey Instrument: IMOJULA YOKUPHA AMAKHUPHONI 
 
Ilanga Lokuhlolwa:     [unyaka/inyanga/usuku] 
 
Igama lomhloli:                   _________________ 
 




B1. Mangaki amanye amadoda aya ocansini namanye owaziyo okewaxoxisana nawo kulenyanga edlule? Ngokuthi 
‘owaziyo’, sisho ukuthi umuntu owazi igama lakho futhi nawe wazi elakhe, futhi ngokuthi ‘uxoxisane naye’ sisho ukuthi 
omazi ngesicu noma enikhuluma naye ocingweni, ukuthumelana imilayezo noma elayinini. 
[faka inimbolo] 
 
B2. Mangaki [B1] kulamadoda oke wahlangana nawo ngokwesiqu? 
[faka inombolo] 
 
B3. Mangaki [B2] kulamadoda aneminyaka ewu18 ukuya phezulu? 
[faka inombolo] 
 
Q9. Mangaki [B3] kulamadoda ahlala e [Johannesburg/Nairobii]? 
[faka inombolo] 
 
Q10. Mangaki [B4] kulamadoda oke wawabona kulamaviki amabili adlule? 
[faka inombolo] 
 
UKUDLULISA AMAKHUPHONI (ABANQABILE) 
Sifuna ukukubuza ngabantu abangavumanga ukwamukela ikhuphoni kuwe. 
 
Q11 Mangaki amadoda obufuna ukuwapha lelikhuphoni anqabile ukuyithatha? 
 [faka inombolo] 
 
Q12 For each of [Q11] Abayithathanga ngani lelikhuphoni?  
Ucabanga umuntu wesilisa wokuqala owazama ukumunika ikhuphoni wanqaba ukulithatha, 
Yini engalithathanga ikhuphoni kuwe? [khetha konke okungenayo] 
Uthe uselibambile iqhaza kulolucwaningo  
Uthe useyitholile lelikhuphoni komunye umuntu 
Uthe akayona indoda eya ocansini namanye amadoda 
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Uthe uneminyaka engaphansi kwa 18 
Uthe akahlali edolobheni engihlala kulo 
Akanaso isifiso sokubamba iqhaza kulolucwaningo 
Uthe akanayo imali eyanele ukuthi angabamba iqhaza 
 Esinye isizathu-sisho 





UKUDLULISA AMAKHUPHONI (ABAWAMKELILE) 
Manje sicela ukukubuza ngabantu abalithathile lelikhuphoni kuwe. 
Q13. Bangaki abesilisa obaphe lelikhuphoni abalithethe? 
[faka inombolo 0-3] 
IF Q13>0  Lomuntu omuphe ikhuphoni yokuqala 
Q14i: Ucabanga ukuthi lomuntu ubezokunika ikhuphoni kube ubebambe iqhaza kuqala kunawe kulolucwaningo? 
Yebo 
Cha 
Q14i: Sisacabanga ngalomuntu wokuqala omunikeze ikhuphoni walamukela: 




Q14i: Sisacabanga ngalomuntu wokuqala omunikeze ikhuphoni walamukela: 
Yini ekwenze wanquma ukupha lomuntu ikhuphoni? Khetha isizathu esibaluleke kakhulu 
  Bekawokuqala okhonayo ukungena kulolucwaningo 
  Ungumngani wami osondele kakhulu 
  Unguphathina wami 
  Ubedinga lemali yokubamba iqhaza 
  Bengicabanga ukuthi khona azokuzuza kulolucwaningo 
  Ngimucele ngokuvulekile yena weza kimina 
Okunye(sicela usho isizathu_________________) 
LOOP Q14i KWABANYE OSAZOBAPHA AMAKHUPHONI 
[IF Q14>1] Okufaka lomuntu wesibili ozomupha ikhuphoni 
[IF Q14>2] Okufaka umuntu wesithathu ozomupha ikhuphoni 
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